

Pier Giuseppe Pelicci, M.D. - Ph.D.

Education

- 1987** PhD Degree in Molecular Biology, University of Perugia, Italy.
1987 Specialty Degree, Board of Internal Medicine, Summa cum laude, University of Perugia, Italy.
1981 Medical Degree, Summa cum laude, University of Perugia, Italy.

Brief chronology of employment

- 2010-today** Scientific Co-Director of the European Institute of Oncology (IEO), Milan, Italy.
2010-today President of TTFactor Srl, the technology transfer company of IEO and IFOM (FIRC Institute for Molecular Oncology).
2000-today Scientific Director of the SEMM Foundation (European School of Molecular Medicine), Milan, Italy.
1995-today Chairman of the Department of Experimental Oncology, IEO, Milan, Italy.
1987-1994 Chief of the Laboratory of Molecular Biology, "Istituto di Clinica Medica I", Perugia, Italy.
1983-1986 Post Doctoral Fellow in Molecular Biology, New York University Medical Center, Department of Pathology, New York, USA.
1982 Post Doctoral Fellow in Experimental Haematology, "Institut National de la Sante et de la Recherche Medicale", Unite de Recherches en Genetique Moleculaire et Hematologie, I.N.S.E.R.M.-U.91, Creteil, France.

Academic Positions held

- 2004-today** Full Professor of Pathology, University of Milan, Milan, Italy.
2000-2003 Full Professor of Pathology, San Raffaele University, Milan, Italy.
2000-2002 Visiting Professor, New York Medical College, New York, USA.
1994-2000 Associate Professor of Oncology, University of Parma, Italy.

Scientific Committee/Board memberships

- 2014-today** Member of the "Carlo Erba Foundation", Milan, Italy.
2012-today Member of the "Melanoma Independent Board-MIB", Milan, Italy.
2012-today Member of the "Polo di Innovazione in Genomica, Genetica e Biologia" Scientific Committee University of Perugia, Italy.
2009-today Member of the "Grazia Focacci Foundation" Scientific Committee, Milan, Italy.
2009-today Member of the Scientific Advisory Board of the Cancer Science Institute of Singapore, Singapore.
2008-2012 Member of the SENDO Board as Representative of IEO, Bellinzona, Switzerland.
2007-today Member of the "Silvio Tronchetti Provera Foundation" Scientific Committee, Milan, Italy.
2003-today President of the "Umberto Veronesi Foundation" Scientific Committee, Milan, Italy.

Active Academy memberships

European Molecular Biology Organization (EMBO); American Association for Cancer Research (AACR); American Society of Hematology (ASH); American Society for Biochemistry and Molecular Biology (ASBMB); European Haematology Association (EHA); European Society for Medical Oncology (ESMO); Italian Association of Cell Biology and Differentiation (ABCD); Academia Europea.

Active memberships to International Journal Editorial Boards

ecancermedicallscience (Founding Editor); *Frontiers in Molecular and Cellular Oncology* (Associate Editor); *Genes Chromosome and Cancer* (Member of the Editorial Board); *Journal of Cellular Physiology* (Associate Editor); *Tumori - A Journal of Experimental and Clinical Oncology* (Member of the Advisory Board).

Awards

2012	Premio Città di Firenze, Firenze, Italy
2012	Premio Cartagine, Roma, Italy
2010	Premio Casentino, Arezzo, Italy.
2009	Premio Stella di Tabor, Amalfi (SA), Italy.
2009	Premio San Valentino d'Oro, Terni, Italy.
2008	Premio Bontà, Gubbio (PG), Italy.
2007	Swiss Bridge Award, Zurich, Switzerland.
2007	Premio Bandiera, Gubbio (PG), Italy.
2006	Premio Angelo dell'Anno by SolidArte ONLUS, Milan, Italy.
2001	Premio Ospedale San Raffaele, Milan, Italy.
2000	Associazione Nuova Spoleto Award for Medical Research, Spoleto (PG), Italy.
2000	Ercole Pisello Award for Excellence in Medicine, Deruta (PG), Italy.
1998	American-Italian Foundation for Cancer Research Award for Excellence in Medicine, New York, USA.
1998	Premio Guido Venosta (Italian Cancer Research Foundation - FIRC), Milan, Italy.
1996	Premio Cassa di Risparmio di Asti Foundation, Asti, Italy.
1996	Premio Chiara d'Onofrio Foundation, Pomezia (RM), Italy.
1992	Cecilia Cioffrese Award for Cancer Research (Carlo Erba Foundation), Milan, Italy.
1989	Fellowship from the Anna Villa Rusconi Foundation, Varese, Italy.
1988	Favretto Foundation Award for oncologists, Turin, Italy.
1987	Fellowship from the Associazione Umbra Lotta Leucemie e Linfomi, Perugia, Italy.
1986	Senior Fellowship for AIDS research from the Kaplan Cancer Center, New York University, New York, USA.
1985	Fellowship from the American-Italian Foundation for Cancer Research, New York, USA.
1984	Fellowship from the "Ministero Italiano della Pubblica Istruzione per il perfezionamento presso istituzioni estere di livello universitario", Rome, Italy.
1983	Fellowship from Fidia spa, Abano Terme (PD), Italy.
1982	Gatti Foundation Award for young haematologists, Bologna, Italy.
1981	International Award for medical students, Ascona, Switzerland.

Scientific Achievements

- Cloning of the human T-cell receptor T-gamma locus and first demonstration of the usage of immunoglobulin and T-cell receptor gene rearrangements for diagnosis of lineage and clonality in lymphoproliferative disorders.
- First demonstration of myc mutations and myb amplification in haematopoietic tumours.
- Cloning of the Acute Promyelocytic Leukaemia 15;17 translocation breakpoints and molecular and biological characterization of their abnormal products (PML/RARa and RARa/PML fusion proteins).
- First demonstration of a mechanistic connection between oncogene expression (PML/RARa) and chromatin changes (modification of acetylation and DNA methylation).
- Definition of the molecular basis of retinoic acid treatment in Acute Promyelocytic Leukaemia and standardization of molecular assays for the monitoring of APL residual disease during treatment.
- Cloning of the Shc gene and definition of the role of Shc proteins in signal transduction from activated tyrosine kinases to Ras.
- Identification of the p66shc splice variant as a critical determinant of the life span control mechanisms in

mammals.

- Definition of the role of the cell cycle inhibitor p21 in the self-renewal regulation of leukemic stem cells.
- Definition of the role of the tumour suppressor p53 in the regulation of polarity of self-renewing divisions in mammary stem cells.

Publications and patents

To date, Dr Pelicci has published 431 peer-reviewed manuscripts (367 original research papers and 64 invited reviews), 29 book chapter publications and he is holder of 10 granted patents. His h-index is currently 100 (Web of Knowledge database).

Patents

1. Group of genomic probes for use in the diagnosis of acute promyelocytic leukaemia and as a component of a diagnostic kit. IT1244704 (B), 1994-08-08.
2. Intracellular interactors and EH domain binding specificity. IT1291110 (B1), 1998-12-29
3. Materials and methods relating to modulation of P66 expression. EP1163335 (B1), 2005-05-25; AU778301 (B2), 2004-11-25.
4. Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease. AU2007207869 (B2), 2009-09-10
5. Valproic acid for the treatment of breast cancer, colon cancer, head and neck cancer, small cell lung carcinoma and cancer of the blood cells in combination with irradiation EP1427403 (B1), 2005-12-28; EP1427403 (B8), 2006-03-22; AU2002338716 (B2), 2007-08-16
6. Topical use of valproic acid for the prevention or treatment of psoriasis and acne. EP1635808 (B1), 2008-10-01
7. Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases. US7858329 (B2), 2010-12-28; JP4738810 (B2), 2011-08-03.
8. Histone Deacetylases Inhibitors. US7803800 (B2), 2010-09-28; AU2005291297 (B2), 2010-12-23; US8058273 (B2), 2011-11-15; CN101039905 (B), 2012-02-08.
9. The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity. AU2003267386 (B2), 2010-07-01.
10. Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT. US7915304 (B2), 2011-03-29.

List of peer-review articles

1982

1. **Pelicci PG**, Tabilio A, Thomopoulos P, Titeux M, Vainchenker W, Rochant H, Testa U. Hemin regulates the expression of transferrin receptors in human hematopoietic cell lines. *FEBS Lett* 145, 350-4, 1982.

1983

2. Donti E, **Pelicci PG**, Mecucci C, Venti G. Sindrome 5q-: Descrizione di un nuovo caso. *Pathologica* 75:266, 1983.
3. Tabilio A, **Pelicci PG**, Vinci G, Mannoni P, Civin CI, Vainchenker W, Testa U, Lipinski M, Rochant H, Breton-Gorius J. Myeloid and megakaryocytic properties of K562 cell lines. *Cancer Res* 43:4569-74, 1983.
4. Testa U, **Pelicci PG**, Thomopoulos P, Titeux M, Rochant H. The number of transferrin receptors on human hematopoietic cell lines is influenced by membrane phospholipids. *Biochemistry International* 7:169-78, 1983.
5. Villevall JL, **Pelicci PG**, Tabilio A, Titeux M, Henri A, Louache F, Thomopoulos P, Vainchenker W, Garbaz M, Rochant H, Breton-Gorius J, Edwards PAW, Testa U. Erythroid properties of K562 cells: effect of hemin, butyrate and TPA induction. *Exp Cell Res* 146:428-35, 1983.

1984

6. Louache F, Testa U, **Pelicci PG**, Thomopoulos P, Titeux M, Rochant H. Regulation of transferrin receptors in human hematopoietic cell lines. *J Biol Chem* 259:11576-82, 1984.
7. Louache F, Villevall JL, **Pelicci PG**, Titeux M, Vainchenker W, Rochant H, Thomopoulos P, Testa U. Characterization of phorbol esters binding to K562 cells. *Anticancer Res* 4:33-40, 1984.

8. **Pelicci PG**, Lanfrancone L, Brathwaite MD, Wolman SR, Dalla Favera R. Amplification of the c-myc oncogene in a case of human acute myelogenous leukemia. Science 224:1117-21, 1984.
9. **Pelicci PG**, Testa U, Thomopoulos P, Tabilio A, Vainchenker W, Titeux M, Gourdin MF, Rochant H. Inhibition of transferrin binding and iron uptake of hematopoietic cell lines by phorbol esters. Leukemia Res 8:597-609, 1984.

1985

10. Flug F, **Pelicci PG**, Bonetti F, Knowles DM, Dalla Favera R. T-cell receptor gene rearrangements as marker of lineage and clonality in T-cell tumors. P Natl Acad Sci USA 82:3460-4, 1985.
11. Knowles DM, Dalla-Favera R, **Pelicci PG**. T-cell receptor beta chain gene rearrangement in T-cell neoplasia. Lancet 2:159-60, 1985.
12. Knowles DM, Dodson L, Burke JS, Wang JW, Bonetti F, **Pelicci PG**, Flug F, Dalla Favera R, Wang CY. Slg-E- ("null cell") non-Hodgkin's lymphomas: Multiparametric determination of their B or T cell lineage. Am J Pathol 120:365-70, 1985.
13. Pantazis P, **Pelicci PG**, Dalla Favera R, Antoniades HN. Synthesis and secretion of proteins resembling platelet-derived growth factor by human glioblastoma and fibrosarcoma cells in culture. P Natl Acad Sci USA 82:2404-8, 1985.
14. **Pelicci PG**, Knowles DM, Dalla Favera R. Lymphoid tumors displaying rearrangements of both immunoglobulin and T-cell receptor genes. J Exp Med 162:1015-24, 1985.
15. Rambaldi A, **Pelicci PG**, Allavena P, Knowles DM, Rossini S, Bassman R, Barbui T, Dalla Favera R, Mantovani A. T-cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells. J Exp Med 162:2156-62, 1985.

1986

16. Falini B, Tabilio A, **Pelicci PG**, Dalla Favera R, Donti E, Rambotti P, Grignani F, Martelli MF. T-cell receptor b -chain gene rearrangement in a case of Ph - positive chronic myeloid leukaemia blast crisis. Brit J Haematol 62:776-80, 1986.
17. Foa R, **Pelicci PG**, Migone N, Lauria F, Pizzolo G, Flug F, Knowles DM, Dalla Favera R. Analysis of T-cell receptor beta chain gene rearrangements demonstrates the monoclonal nature of T-cell chronic lymphoproliferative disorders. Blood 67:247-50, 1986.
18. Knowles DM, Neri A, **Pelicci PG**, Burke JS, Wu A, Winberg CD, Sheibani K, Dalla Favera R. Immunoglobulin and T-cell receptor b -chain gene rearrangement analysis of Hodgkin's disease: Implication for lineage determination and differential diagnosis. P Natl Acad Sci USA 83:7942-6, 1986.
19. Knowles DM, **Pelicci PG**, Dalla Favera R. T-cell receptor beta chain gene rearrangements: genetic markers of T-cell lineage and clonality. Hum Pathol 17(6):546-51, 1986.
20. Pantazys P, Lanfrancone L, **Pelicci PG**, Dalla-Favera R, Antoniades HN. Human Leukemic cells synthesize and secrete proteins related to platelet derived growth-factor. P Natl Acad Sci USA 83:5526-30, 1986.
21. **Pelicci PG**, Knowles DM, Arlin ZA, Wiczorek R, Luciw P, Dina D, Basilico C, Dalla Favera R. Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in AIDS related lymphoproliferative disorders. J Exp Med 164:2049-76, 1986.
22. **Pelicci PG**, Knowles DM, Magrath I, Dalla Favera R. Chromosomal Breakpoints and structural alterations of the myc locus differ in endemic and sporadic forms of Burkitt Lymphoma. P Natl Acad Sci USA 83:2984-8, 1986.
23. Rambaldi A, Allavena P, Pirelli A, Di Bello M, Rossini S, Bassan R, Barbui T, **Pelicci PG**, Dalla Favera R, Mantovani A. Immunological and genotypic analysis of human T gamma-lymphoproliferative disorders. Ric Clin Lab 16(1):29-35, 1986.

1987

24. Barletta C, **Pelicci PG**, Kenyon L, Smith SD, Dalla Favera R. Relationship between the c-myc locus and the 6q-chromosomal aberration in leukemias and lymphomas. Science 235:1064-7, 1987.
25. Bonetti F, Chilosi M, Menestrina F, Scarpa A, **Pelicci PG**, Amorosi E, Fiore-Donati L, Knowles DM. Immunohistological analysis of Rosai-Dorfman histiocytosis. A disease of S-100 + CD1-histiocytes. Virchows Arch A Pathol Anat Histopathol 411(2):129-35, 1987.
26. Neri A, Jakobiec FA, **Pelicci PG**, Dalla Favera R, Knowles DM. Immunoglobulin and T-cell receptor beta chain gene rearrangement analysis of ocular adnexal lymphoid neoplasms: clinical and biological implications. Blood 70:1519-29, 1987.
27. **Pelicci PG**, Allavena P, Subar M, Rambaldi A, Pirelli A, Di Bello M, Barbui T, Knowles DM, Dalla Favera R, Mantovani A. T-cell receptor (alpha, beta, gamma) gene rearrangements and expression in normal and leukemic Large Granular Lymphocytes/Natural Killer cells. Blood 70:1500-8, 1987.

28. **Pelicci PG**, Neri A, Knowles DM, Littman DR, Dalla Favera R, Subar M. Arrangements and rearrangements of the human T-cell receptor gamma gene. Ann NY Acad Sci 511:232-45, 1987.
29. **Pelicci PG**, Subar M, Weiss A, Dalla Favera R, Littman D. Molecular diversity of the human T-gamma gene. Science 237:1051-5, 1987.
30. Serementis SV, **Pelicci PG**, Tabilio A, Ubriaco A, Grignani F, Cuttner J, Winchester RJ, Knowles DM, Dalla Favera R. High frequency of clonal immunoglobulin or T-cell receptor gene rearrangements in acute myelogenous leukemia expressing terminal deoxyribonucleotidyltransferase (TDT). J Exp Med 165:1703-12, 1987.

1988

31. Donti E, Falini B, **Pelicci PG**, Donti GV, Rosetti A, Martelli M, Grignani F. Immunological and molecular studies in a case of follicular lymphoma with an extra chromosome 12 and t(2;8) translocation. Leukemia 2:41-4, 1988.
32. Knowles DM, Glenn A, Chamulak GA, Subar M, Burke JS, Dugan M, Wernz J, Slywotzky C, **Pelicci PG**, Dalla Favera R, Raphael B. Lymphoid Neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center with 105 patients (1981-1986). Ann Intern Med 108:744-53, 1988.
33. Pannuti A, Lanfranccone L, Pascucci A, **Pelicci PG**, La Mantia G, Lania L. Isolation of cDNAs encoding finger proteins and measurement of the corresponding mRNA levels during myeloid terminal differentiation. Nucleic Acid Res 16:4227-37, 1988.
34. Subar M, **Pelicci PG**, Neri A, Allavena P, Littman D, Knowles DM, Dalla Favera R. Patterns of T cell receptor gamma gene rearrangement and expression in B and T lymphoid malignancies. Leukemia 2:19-26, 1988.

1989

35. Donti E, Longo L, Lanfranccone L, Tonini GP, Pascucci A, Grignani F, Lania L, **Pelicci PG**. Localization of the human HF.2 finger gene on the band 1p34p35 deleted in neuroblastoma tumor. Clin Chem Enzym Comms 2:55-7, 1989.
36. Donti E, Montanucci M, Longo L, Mencarelli A, Pandolfi PP, Tabilio A, Nanni M, Alimena G, Avanzi G, Pegoraro L, Grignani F, **Pelicci PG**. The myeloperoxidase gene in acute promyelocytic leukemia. Science 244:823-6, 1989.
37. Falini B, Flenghi L, Fagioli M, Martelli MF, Pileri S, Grignani F, Beltrami A, Novero D, **Pelicci PG**. T-Lymphoblastic lymphomas expressing the non disulfide-linked form of the T-cell receptor g/d. Characterization with monoclonal antibodies and genotypic analysis. Blood 74:2501-7, 1989.
38. Falini B, Flenghi L, Fagioli M, Stein H, Swarting R, Riccardi C, Mannocchio I, **Pelicci PG**, Lanfranccone L. Evolutionary conservation of the human proliferation associated epitope recognized by Ki-67 monoclonal antibody J Histochem Cytochem 37:1471-8, 1989.
39. Falini B, Flenghi L, Pileri S, **Pelicci PG**, Fagioli M, Martelli MF, Moretta L, Ciccone E. Distribution of T-cells bearing different forms of the T-cell receptor g/d in normal and pathological human tissues. J Immunol 143:2480-8, 1989.
40. Lanfranccone L, Grignani F, **Pelicci PG**. Hemopoietic growth factors expression in normal human phagocytic cells. Int J Immunopath Ph 2:55-61, 1989.
41. Lanfranccone L, Mannoni P, Pebusque MJ, Carè A, Peschle C, Grignani F, **Pelicci PG**. Expression pattern of c- fes oncogene mRNA in human myeloid cells. Int J Cancer 4:35-8, 1989.

1990

42. Alcalay M, Antolini F, Van de Ven WJ, Lanfranccone L, Grignani F, **Pelicci PG**. Characterization of human and mouse c-fes cDNA clones and identification of the 5' end of the gene. Oncogene 5:267-75, 1990.
43. Carè A, **Pelicci PG**, Meccia E, Fagioli M, Testa U, Ciccone E, Moretta A, Moretta L, Peschle C. Natural Killer cells carry the germ line configuration of the T-cell receptor delta chain gene and heterogeneously express six distinct d transcripts. Eur J Immunol 20:939-42, 1990.
44. Donti E, Lanfranccone L, Huebner K, Pascucci A, Venti G, Pengue G, Grignani F, Croce CM, Lania L, **Pelicci PG**. Localization of the human HF.10 finger gene on a chromosome region (3p21-22) frequently deleted in human cancers. Hum Genet 84:391-5, 1990.
45. Fagioli M, Carè A, Ciccone E, Moretta L, Moretta A, Testa U, Falini B, Grignani F, Peschle C, **Pelicci PG**: Molecular studies on LAK cells. Ann Ist Super Sanità, 26:357-68, 1990.
46. Fagioli M, Ciccone E, Bottino C, Falini B, Grignani F, Moretta A, Moretta L, **Pelicci PG**. The Cg1 encoded disulphide-linked and the Cg2 encoded non disulphide linked forms of the g/d heterodimer use different g and d variable regions. Blood 76:279-84, 1990.
47. Lania L, Donti E, Pannuti A, Pascucci A, Pengue G, Feliciello I, La Mantia G, Lanfranccone L, **Pelicci PG**. cDNA isolation, expression analysis and chromosomal localization of two human zinc-finger genes. Genomics 6:333-40, 1990.

48. Longo L, Donti E, Mencarelli A, Avanzi G, Pegoraro L, Alimena G, Tabilio A, Venti G, Grignani F, **Pelicci PG**. Mapping of chromosome 17 breakpoints in acute myeloid leukemias. *Oncogene* 5:1557-63, 1990.
49. Longo L, Pandolfi PP, Biondi A, Rambaldi A, Mencarelli A, Lo Coco F, Diverio D, Pegoraro L, Avanzi G, Tabilio A, Zangrilli D, Alcalay M, Donti E, Grignani F, **Pelicci PG**. Rearrangements and aberrant expression of the RARA gene in acute promyelocytic leukemias. *J Exp Med* 172:1571-5, 1990.
50. Pelicci G, Pagliacci MC, Lanfrancone L, **Pelicci PG**, Grignani F, Nicoletti I. Inhibitory effect of the somatostatin analog octreotide on rat pituitary tumor cell (GH) proliferation in vitro. *J Endocrinol Invest* 13:657-62, 1990.
51. Testa U, Carè A, Montesoro E, Fossati C, Giannella G, Masciulli R, Fagioli M, Bulgarini D, Habetswallner D, Isacchi G, **Pelicci PG**, Peschle C. IL-2 dependent long-term cultures of low-density lymphocytes allow the proliferation of LAK cells with NK, Ti g/d or TNK phenotype. *Cancer Immunol Immun* 31:11-8, 1990.

1991

52. Alcalay M, Zangrilli D, Pandolfi PP, Longo L, Mencarelli A, Giacomucci A, Rocchi M, Biondi A, Rambaldi A, Lo Coco F, Diverio D, Donti E, Grignani F, **Pelicci PG**. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. *P Natl Acad Sci USA* 88:1977-81, 1991.
53. Aversa F, **Pelicci PG**, Terenzi A, Carotti A, Felicini R, Mencarelli A, Donti E, Latini P, Aristei C, Martelli MF. Results of T-depleted BMT in chronic myelogenous leukemia after a conditioning regimen that included thiotepa. *Bone Marrow Transplant* 7(Suppl 2):24, 1991.
54. Biondi A, Rambaldi A, Alcalay M, Pandolfi PP, Lo Coco F, Diverio D, Rossi V, Mencarelli A, Longo L, Zangrilli D, Masera G, Barbui T, Mandelli F, Grignani F, **Pelicci PG**. RAR-a gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukaemia. *Blood* 77:1418-22, 1991.
55. Donti E, Lanfrancone L, **Pelicci PG**, Birnie GD, Dalla Favera R. Loss of amplification and appearance of a novel translocation site of the c-myc oncogene in HL-60 leukemia cells. *Cancer Genet Cytogen* 56:57-64, 1991.
56. Donti E, Longo L, **Pelicci PG**. Chromosomal localization of the APL t(15;17) breakpoints by molecular cytogenetic analysis. *Cancer Genet Cytogen* 54:265-6, 1991.
57. Fagioli M, Carè A, Ciccone E, Moretta L, Meccia E, Testa U, Falini B, Grignani F, Peschle C, **Pelicci PG**. Molecular heterogeneity of the 1.0 Kb Tb transcript in natural killer and g/d lymphocytes. *Eur J Immunol* 21:1529-34, 1991.
58. Falini B, Flenghi L, Fagioli M, **Pelicci PG**, Stein H, Bigerna B, Pileri S, Martelli MF. Expression of the intestinal T-lymphocyte associated molecule HML-1: analysis of 75 non-Hodgkin's lymphomas and description of the first HML-1 positive T-lymphoblastic tumour. *Histopathology* 18:421-6, 1991.
59. Hughes TP, Ambrosetti A, Barbù D, Bartram C, Battista R, Biondi A, Chiamenti A, Cimino G, Ernst P, Frassoni F, Gasparini P, Gentilini I, Gluckman E, Grosvelt G, Guerrasio A, Hegewich S, Janssen JWG, Keating A, LoCoco F, Martiat P, Martinelli G, Mills K, Morgan G, Nadali G, **Pelicci PG**, Perona G, Pignatti PF, Richard P, Saglio G, Trabetti E, Turco A, Veneri D, Zaccaria A, Zander A, Goldman JM. Clinical value of PCR in diagnosis and follow-up of leukemia and lymphoma: report of the third workshop of the molecular biology-BMT study group. *Leukemia* 5:448-51, 1991.
60. Lo Coco F, Avvisati G, Diverio D, Petti MC, Alcalay M, Pandolfi PP, Zangrilli D, Biondi A, Rambaldi A, Moleti ML, Mandelli F, **Pelicci PG**. Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukaemia. *Blood* 77:1657-9, 1991.
61. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, Grignani F, **Pelicci PG**. Structure and origin of the acute promyelocytic leukemia myl/RARa cDNA and characterization of its retinoid-binding and transactivation properties. *Oncogene* 6:1285-92, 1991.

1992

62. Alcalay M, Zangrilli D, Fagioli M, Pandolfi PP, Mencarelli A, Lo Coco F, Biondi A, **Pelicci PG**. Expression pattern of the RARa/PML fusion gene in acute promyelocytic leukemia. *P Natl Acad Sci USA* 89:4840-4, 1992.
63. Biondi A, Grignani F, Rambaldi A, Pandolfi PP, Rossi V, Giudici G, Alcalay M, Lo Coco F, Diverio D, Pogliani EM, Lanzi EM, Mandelli F, Masera G, Barbui T, **Pelicci PG**. Molecular monitoring of the Myl/RARa fusion gene in acute promyelocytic leukemia by the polymerase chain reaction. *Blood* 80:492-97, 1992.
64. Diverio D, LoCoco F, D'Adamo F, Biondi A, Fagioli M, Grignani F, Rambaldi A, Rossi V, Avvisati G, Petti MC, Testi AM, Liso V, Specchia G, Fioritoni G, Recchia A, Frassoni F, Ciolli S, **Pelicci PG**. Identification of DNA rearrangements at the RARa locus in all patients with acute promyelocytic leukemia (APL) and mapping of APL breakpoints within the RARa second intron. *Blood* 79:3331-6, 1992.
65. Fagioli M, Alcalay M, Pandolfi PP, Venturini L, Mencarelli A, Simeone A, Acampora D, Grignani F, **Pelicci PG**. Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. *Oncogene* 7:1083-1091, 1992.

66. Jonjic N, Peri G, Bernasconi S, Sciacca FL, Colotta F, **Pelicci PG**, Lanfrancone L, Mantovani A. Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. *J Exp Med* 176:1165-74, 1992.
67. Lanfrancone L, Boraschi D, Ghiara P, Falini B, Grignani F, Peri G, Mantovani A, **Pelicci PG**. Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1. *Blood* 80:2835-42, 1992.
68. Lanfrancone L, Pengue G, Pandolfi PP, Salcini AE, Giacomucci A, Longo L, Donti E, De Luca P, La Mantia G, **Pelicci PG**, Lania L. Structural and functional organization of the HF.10 human zinc finger gene located on chromosome 3p21-p22. *Genomics* 12:720-8, 1992.
69. Lo Coco F, Diverio D, D'Adamo F, Avvisati G, Alimena G, Nanni M, Alcalay M, Pandolfi PP, **Pelicci PG**. PML/RARa rearrangement in acute promyelocytic leukemias apparently lacking the t(15;17) translocation. *Eur J Haematol* 48:173-6, 1992.
70. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Meloni G, Mandelli F, Grignani F, Masera G, Barbui T, **Pelicci PG**. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. *Lancet* 340:1437-8, 1992.
71. Mc Glade J, Cheng A, Pelicci G, **Pelicci PG**, Pawson T. SHC proteins are phosphorylated and regulated by the v-Src and v-fps protein tyrosine kinases. *P Natl Acad Sci USA* 89:8869-73, 1992.
72. Nervi C, Poindexter EC, Grignani F, Pandolfi PP, LoCoco F, Avvisati G, **Pelicci PG**, Jetten AM. Characterization of the PML/RARa chimeric product of the acute promyelocytic leukemia specific t(15;17) translocation. *Cancer Res* 52:3687-92, 1992.
73. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F, Rochette-Egly C, Gaube MP, Chambon P, **Pelicci PG**. Genomic variability and alternative splicing generate multiple PML/RARa transcripts that encode aberrant PML proteins and PML/RARa isoforms in acute promyelocytic leukaemia. *EMBO J* 11:1397-408, 1992.
74. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T, **Pelicci PG**. A Novel Transforming Protein (SHC) with a SH2 Domain Is Implicated in Mitogenic Signal Transduction. *Cell* 70:93-104, 1992.
75. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, **Pelicci PG**, Schlessinger J, Pawson T. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinase. *Nature* 360:689-92, 1992.

1993

76. Davis S, Crino L, Tonato M, Darwish S, **Pelicci PG**, Grignani F. A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small-cell lung cancer. *Am J Clin Onco* 116:93-5, 1993.
77. Delia D, Aiello A, Lombardi L, **Pelicci PG**, Grignani F, Grignani F, Formelli F, Menard S, Costa A, Veronesi U, Pierotti MA. N-(4-Hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. *Cancer Res* 53:6036-41, 1993.
78. Dermime S, Grignani F, Clerici M, Nervi C, Sozzi G, Talamo GP, Marchesi E, Formelli F, Parmiani G, **Pelicci PG**, Gambacorti-Passerini C. Occurrence of Resistance to Retinoic Acid in the Acute Promyelocytic Leukemia Cell Line NB4 Is Associated With Altered Expression of the PML/RARa Protein. *Blood* 82:1573-7, 1993.
79. Diverio D, Pandolfi PP, Biondi A, Avvisati G, Petti MC, Mandelli F, **Pelicci PG**, Lo Coco F. Absence of RT-PCR detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. *Blood* 82:3556-9, 1993.
80. Gambacorti-Passerini GC, Grignani F, Arienti F, Pandolfi PP, **Pelicci PG**, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein PML/RARa present in acute promyelocytic leukemia cells. *Blood* 81:1369-75, 1993.
81. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, **Pelicci PG**. The acute promyelocytic leukaemia specific PML/RARa fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. *Cell* 74:423-31, 1993.
82. Hubner K, Druck T, LaForgia S, Lasota J, Croce CM, Lanfrancone L, Donti E, Pengue G, La Mantia G, **Pelicci PG**, Lania L. Chromosomal localization of four human zinc finger cDNAs. *Hum Genet* 91:217-22, 1993.
83. Lo Coco F, **Pelicci PG**, D'Adamo F, Diverio D, Alimena G, Montefusco E, Arcese W, Avvisati G, DeFelice L, Meloni G, Nervi C, Mandelli F, Saglio G. Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangements. *Blood* 82:606-12, 1993.
84. Longo L, Trecca D, Biondi A, Lo Coco F, Grignani F, Maiolo AT, **Pelicci PG**, Neri A. Frequency of RAS and p53 mutations in acute promyelocytic leukemias. *Leuk Lymphoma* 11:405-10, 1993.

85. Segatto O, Pelicci G, Giuli S, Digiesi G, Di Fiore PP, McGlade J, Pawson T, **Pelicci PG**. Shc products are substrates of erbB-2 kinase. *Oncogene* 8:2105-12, 1993.

1994

86. Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti MG, **Pelicci PG**, Pierotti A. The oncogenic versions of the RET and TRK tyrosine kinases bind SHC and GRB2 adaptor proteins. *Oncogene* 9:1661-68, 1994.
87. Dilworth S, Brewster C, Jones M, Lanfrancone L, Pelicci G, **Pelicci PG**. Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc. *Nature* 367:87-90, 1994.
88. Diverio D, Pandolfi PP, Rossi V, Biondi A, **Pelicci PG**, Lo Coco F. Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. *Leukemia* 8(7):1105-7, 1994.
89. Fagioli M, Grignani F, Ferrucci PF, Alcalay M, Mencarelli A, Nicoletti I, Grignani F, **Pelicci PG**. Effect of the acute promyelocytic leukemia PML/RAR alpha protein on differentiation and survival of myeloid precursors. *Leukemia* 8(Suppl 1):S7-11, 1994.
90. Giorgetti S, **Pelicci PG**, Pelicci G, Van Obberghen E. Involvement of SHC proteins in signaling through the insulin receptor and the IGF-I receptor. *Eur J Biochem* 223:195-202, 1994.
91. Huebner K, Kastury K, Druck T, Salcini AE, Lanfrancone L, Pelicci G, Lowenstein E, Li W, Park SH, Cannizzaro L, **Pelicci PG**, Schlessinger J. Chromosome locations of genes encoding human signal transduction adapter proteins, Nck (NCK), Shc (SHC1), and Grb2 (GRB2). *Genomics* 22:281-7, 1994.
92. Lo Coco F, D'Adamo F, Diverio D, **Pelicci PG**, Saglio G. Polyclonal hemopoiesis in leukemia patients following molecularly documented remission. *Leukemia* 8(Suppl 1):S137-9, 1994.
93. Puil L, Liu J, Gish G, Mbalamu G, Bowtel D, **Pelicci PG**, Arlinghaus R, Pawson T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. *Embo J* 13:764-73, 1994.
94. Salcini AE, McGlade J, Pelicci G, Nicoletti I, Pawson T, **Pelicci PG**. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. *Oncogene* 9:2827-36, 1994.
95. Testa U, Grignani F, Barberi T, Fagioli M, Masciulli R, Ferrucci PF, Seripa D, Camagna A, Alcalay M, **Pelicci PG**, Peschle C. PML/RARa U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to Vitamin D. *Cancer Res* 54:4508-15, 1994.
96. Trecca D, Longo L, Biondi A, Cro L, Grignani F, Maiolo AT, **Pelicci PG**, Neri A. Analysis of p53 gene mutations in acute myeloid leukemia. *Am J Hematol* 46:304-9, 1994.
97. Vainikka S, Joukov V, Wennström S, Bergman M, **Pelicci PG**, Alitalo K. Signal transduction by fibroblast growth factor receptor-4(FGFR-4): comparison with FGFR-1. *J Biol Chem* 269:18320-6, 1994.

1995

98. Avantaggiato V, Pandolfi PP, Ruthardt M, Hawe N, Acampora D, **Pelicci PG**, Simeone A. Developmental analysis of the murine Promyelocyte Leukaemia Zinc Finger (PLZF) gene expression: implications for the neuromeric model of the forebrain organization. *J Neurosci* 15(7):4927-42, 1995.
99. Baldari CT, Pelicci G, Di Somma MM, Milia E, Giuli S, **Pelicci PG**, Telford JL. Inhibition of CD4/p56lck signaling by a dominant negative mutant of the Shc adaptor protein. *Oncogene* 10:1141-7, 1995.
100. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandelli F, **Pelicci PG**, Lo Coco F. Detection of Homozygous deletions of the Cyclin-Dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. *Blood* 85:2685-90, 1995.
101. Flenghi L, Fagioli M, Tomassoni L, Pileri S, Gambacorta M, Pacini R, Grignani F, Casini T, Ferrucci PF, Martelli MF, **Pelicci PG**, Falini B. Characterization of a New Monoclonal Antibody (PG-M3) Directed Against the Aminoterminal Portion of the PML Gene Product: Immunocytochemical Evidence for High Expression of PML Proteins on Activated Macrophages, Endothelial Cells, and Epithelia. *Blood* 85:1871-80, 1995.
102. Flenghi L, Ye BH, Fizzotti M, Bigerna B, Cattoretto G, Venturi S, Pacini R, Pileri S, Lo Coco F, Pescarmona E, **Pelicci PG**, Dalla Favera R, Falini B. A specific monoclonal antibody (PG-B6) detects expression of the BCL -6 protein in germinal center B cells. *Am J Pathol* 147:405-10, 1995.
103. Grignani F, Testa U, Fagioli M, Barberi T, Masciulli R, Mariani G, Peschle C, **Pelicci PG**. Promyelocytic Leukemia specific PML/RARa fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells. *Cancer Res* 55:440-3, 1995.
104. Lafage M, Alcalay M, Brunel V, Longo L, Sainty D, Simonetti J, Birg F, **Pelicci PG**. Acute promyelocytic leukaemia cases with non-reciprocal PML/RARa or RARa/PML fusion genes. *Blood* 85:1169-74, 1995.
105. Lanfrancone L, Pelicci G, Brizzi MF, Casciari C, Arouca G, Giuli S, Pegoraro L, Pawson T, **Pelicci PG**. Overexpression of Shc proteins potentiates the proliferative response to the granulocyte-macrophage colony-

- stimulating factor and recruitment of Grb2/SOS and Grb2/p140 complexes to the b receptor subunit. *Oncogene* 10:907-17, 1995.
106. Lavau C, Marchio A, Fagioli M, Jansen J, Falini B, Lebon P, Grosveld F, Pandolfi PP, **Pelicci PG**, Dejean A. The acute Promyelocytic Leukaemia-associated PML gene is induced by interferon. *Oncogene* 11:871-6, 1995.
 107. Lo Coco F, Diverio D, Avvisati G, Mandelli F, Biondi A, **Pelicci PG**. On the differentiative mode of action of All-trans retinoic acid in acute promyelocytic leukemia. *Blood* 86:3264-5, 1995.
 108. Matoskova B, Wong WT, Salcini AE, **Pelicci PG**, Di Fiore PP. Constitutive phosphorylation of eps8 in tumor cell lines: relevance to malignant transformation. *Mol Cell Biol* 15:3805-12, 1995.
 109. Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, Panayotou G, Waterfield MD, Ponzetto C, **Pelicci PG**, Comoglio PM. The Mitogenic and Mitogenic responses HGF are amplified by the SHC adaptor protein. *Oncogene* 10:1631-8, 1995.
 110. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Borrello MG, Segatto O, Di Fiore PP, **Pelicci PG**. Constitutive Phosphorylation of Shc proteins in human tumors. *Oncogene* 11:899-907, 1995.
 111. Ricci A, Lanfrancone L, Chiari R, Belardo G, Pertica C, Natali PG, **Pelicci PG**, Segatto O. Analysis of Protein-Protein interactions involved in the activation of the SHC/Grb-2 pathway by the ERB-2 Kinase. *Oncogene* 11, 1519-29, 1995.
 112. Rogaia D, Grignani F, Grignani F, Nicoletti I, **Pelicci PG**. The acute promyelocytic leukemia-specific PML/RARa fusion protein reduces the frequency of commitment to apoptosis upon growth-factor deprivation of GM-CSF dependent myeloid cells. *Leukemia* 9:1467-72, 1995.
 113. Wong TW, Schumacher C, Salcini AE, Romano A, Castagnino P, **Pelicci PG**, Hanafusa H, Di Fiore PP. A protein binding domain, EH identified in the receptor tyrosine kinase substrate eps15 and conserved in evolution. *P Natl Acad Sci USA* 92:9530-4, 1995.

1996

-
114. Benedetti L, Grignani F, Scicchitano BM, Jetten AM, Diverio D, Lo Coco F, Avvisati F, Gambacorti-Passerini C, Adamo S, Levin AA, **Pelicci PG**, Nervi C. Retinoic-induced differentiation of acute promyelocytic leukemia involves PML-RARa-mediated increase of type II transglutaminase. *Blood* 87:1939-50, 1996.
 115. Brizzi MF, Dentelli P, Lanfrancone L, Rosso A, **Pelicci PG**, Pegoraro L. Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO- mediated myeloid cell proliferation. *Oncogene* 13, 2067-76, 1996.
 116. Chen Y, Grall D, Salcini AE, **Pelicci PG**, Pouyssegur J, Van Obberghen-Schilling E. Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein-coupled thrombin receptor. *EMBO J* 15:1037-44, 1996.
 117. Falini B, Bigerna B, Pasqualucci L, Fizzotti M, Martelli MF, Pileri S, Pinto A, Carbone A, Venturi S, Pacini R, Cattoretti G, Pescarmona E, Lo Coco F, **Pelicci PG**, Anagnostopoulos I, Dalla Favera R, Flenghi L. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. *Blood* 87:465-71, 1996.
 118. Flenghi L, Bigerna B, Fizzotti M, Venturi S, Pasqualucci L, Pileri S, Ye BH, Gambacorti M, Pacini R, Baroni CD, Pescarmona E, Anagnostopoulos I, Stein H, Asdrubali G, Martelli MF, **Pelicci PG**, Dalla Favera R, Falini B. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. *Am. J. Pathol.* 148, 1543-55, 1996.
 119. Fournier E, Rosnet O, Marchetto S, Turck CW, Rottapel R, **Pelicci PG**, Birnbaum D, Borg JP. Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT/VEGFR3 receptor tyrosine kinase. *J Biol Chem* 271:12956-63, 1996.
 120. Gambacorti M, Flenghi L, Fagioli M, Pileri S, Leoncini L, Bigerna B, Pacini R, Natali Tanci L, Pasqualucci L, Ascani S, Mencarelli A, Liso A, **Pelicci PG**, Falini B. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. *Am J Pathol* 149(6):2023-35, 1996.
 121. Grignani F, Testa U, Rogaia D, Ferrucci PF, Samoggia P, Pinto A, Aldinucci D, Gelmetti V, Fagioli M, Alcalay M, Seeler J, Grignani F, Nicoletti I, Peschle C, **Pelicci PG**. Effects on differentiation of the promyelocytic leukemia PML/RARa protein depend on the fusion of the PML protein-dimerization and RARa DNA binding domains. *EMBO J* 15:4949-58, 1996.
 122. Lotti LV, Lanfrancone L, Migliaccio E, Zompetta C, Pelicci G, Salcini AE, Falini B, **Pelicci PG**, Torrisi MR. Shc proteins are localized on endoplasmic reticulum membranes and are redistributed following tyrosine kinase receptor activation. *Mol Cell Biol* 16:1946-54, 1996.
 123. Milia E, Di Somma M, Baldoni F, Chiari R, Lanfrancone L, **Pelicci PG**, Telford J, Baldari C. The aminoterminal phosphotyrosine binding domain of Shc associates with ZAP-70 and mediates TCR dependent gene activation. *Oncogene* 13, 767-75, 1996.

124. Morosetti R, Grignani F, Liberatore C, **Pelicci PG**, Schiller GJ, Kizaki M, Bartram CR, Miller CW, Koeffler HP. Infrequent alterations of the RARa gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes and cell lines. Blood 87:4399-403, 1996.
125. Pelicci G, Dente L, De Giuseppe A, Verducci-Galletti B, Giuli S, Mele S, Vetriani C, Giorgio M, Pandolfi PP, Cesareni G, **Pelicci PG**. A family of Shc related proteins (ShcA, ShcB and ShcC) with conserved PTB, CH1 and SH2 regions. Oncogene 13:633-41, 1996.
126. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, **Pelicci PG**, Miller WH Jr. The PML/RARa oncoprotein is a direct molecular target of retinoic acid in Acute Promyelocytic Leukemia cells. Blood 88:2826-32, 1996.
127. Terenzi A, Aversa F, Mencarelli A, **Pelicci PG**, Velardi A, Perruccio K, Martelli MF. Unusual split chimaerism after mismatched T-depleted BMT. Bone Marrow Transpl 18:465-7, 1996.
128. Tribioli C, Droetto S, Biancone S, Cesareni G, Torrisi MR, Lotti LV, Lanfrancone L, Toniolo D, **Pelicci PG**. An X chromosome-linked gene encoding a protein with characteristic of a rhoGAP predominantly expressed in hematopoietic cells. P Natl Acad Sci USA 93:695-9, 1996.

1997

129. Benedetti L, Levin AA, Scicchitano BM, Grignani F, Allenby G, Diverio D, Lo Coco F, Avvisati G, Ruthardt M, Adamo S, **Pelicci PG**, Nervi C. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Blood 90:1175-85, 1997.
130. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, **Pelicci PG**, Atwater S, Bishop MJ. A PML/RARa transgene initiates murine Acute Promyelocytic Leukemia. P Natl Acad Sci USA 94:2551-6, 1997.
131. Carbone R, Fré S, Iannolo G, Belleudi F, Mancini P, **Pelicci PG**, Torrisi MR, Di Fiore PP. Eps15 and eps15R are essential components of the endocytic pathway. Cancer Res 57:5498-504, 1997.
132. Dente L, Vetriani C, Zucconi A, Pelicci G, Lanfrancone L, **Pelicci PG**, Cesareni G. Modified phage peptides libraries as a tool to study specificity of phosphorylation and recognition of tyrosine containing peptides. J Mol Biol 269:694-703, 1997.
133. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, Pasqualucci L, Biondi A, Riganelli D, Orleth A, Liso A, Martelli MF, **Pelicci PG**, Pileri S. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (Anti-PML). Blood 90:4046-53, 1997.
134. Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, **Pelicci PG**. Cell death induction by the acute promyelocytic leukemia-specific PML/RARa fusion protein. P Natl Acad Sci USA 94:10901-6, 1997.
135. Giordano V, De Falco G, Chiari R, Quinto I, **Pelicci PG**, Bartholomew L, Del Mastro P, Gadina M, Scala G. Shc mediates the Interleukin-6 (IL-6) signalling by interacting with gp130 and Jak2 kinase. J Immunol 158, 4097-103, 1997.
136. Grisolano JL, Wesselschmidt RL, **Pelicci PG**, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARa under control of cathepsin G regulatory sequences. Blood 89:376-87, 1997.
137. He LZ, Tribioli C, Rivi R, Peruzzi D, **Pelicci PG**, Soares V, Cattoretti G, Pandolfi PP. Acute leukemia with promyelocytic features in PML/RARa transgenic mice. P Natl Acad Sci USA 94:5302-7, 1997.
138. Iannolo G, Salcini AE, Gaidarov I, Goodman OB Jr, Baulida J, Carpenter G, **Pelicci PG**, Di Fiore PP, Keen JH. Mapping of the molecular determinants involved in the interaction between eps15 and AP-21. Cancer Res 57:240-5, 1997.
139. Lopez-Illasaca M, Crespo P, **Pelicci PG**, Gutkind JS, Wetzker R. Phosphoinositide 3-kinase g links G protein-coupled receptors to the MAP kinase signalling pathway. Science 275:394-6, 1997.
140. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Brocchia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, **Pelicci PG**, Biondi A, Lo Coco F. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 90:1014-21, 1997.
141. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, Pawson T, Di Fiore PP, Lanfrancone L, **Pelicci PG**. Opposite effects of the p52-/p46- splicing isoforms on the EGF receptor-MAP kinase-*fos* signalling pathway. Embo J 16:706-16, 1997.
142. Rogaia D, Grignani F, Carbone R, Riganelli D, Lo Coco F, Nakamura T, Croce CM, Di Fiore PP, **Pelicci PG**. The localization of the HRX/ALL1 protein to specific nuclear subdomain is altered by fusion with its eps15 translocation partner. Cancer Res 57, 799-802, 1997.
143. Ruthardt M, Testa U, Nervi C, Ferrucci PF, Grignani F, Puccetti E, Grignani F, Peschle C, **Pelicci PG**. Opposite effects of the Acute Promyelocytic Leukemia PML/RARa and PLZF/RARa fusion proteins on retinoic acid signalling. Mol Cell Biol 17:4859-69, 1997.

144. Salcini AE, Confalonieri S, Doria M, Santolini E, Tassi E, Minenkova O, Cesareni G, **Pelicci PG**, Di Fiore PP. Binding specificity and *in vivo* targets of the EH domain, a novel protein-protein interaction module. Gene Dev 11:2239-49, 1997.
145. Tortora G, Damiano V, Bianco C, Baldassarre G, Bianco AR, Lanfrancone L, **Pelicci PG**, Ciardiello F. The R1alpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene 14:923-8, 1997.

1998

146. Alcalay M, Tomassoni L, Colombo E, Stoldt S, Grignani F, Fagioli M, Szekeley L, Helin K, **Pelicci PG**. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol 18:1084-93, 1998.
147. Coda L, Salcini AE, Confalonieri S, Pelicci G, Sorkina T, Sorkin A, **Pelicci PG**, Di Fiore PP. Eps15R is a tyrosine kinase substrate with characteristics of a docking protein possibly involved in coated pits-mediated internalization. J Biol Chem 273:3003-12, 1998.
148. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, **Pelicci PG**, Mandelli F, Biondi A, Lo Coco F. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 92:784-9, 1998.
149. Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D, Grignani F, Pozzan T, Nicoletti I, Grignani F, **Pelicci PG**. Cooperation between the RING+B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene 16:2905-13, 1998.
150. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, Carbone R, Paulli M, Magrini U, Menestrina F, Giardini R, Pilotti S, Mezzelani A, Ugolini B, Billi M, Pucciarini A, Pacini R, **Pelicci PG**, Flenghi L. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol 153:875-86, 1998.
151. Gelmetti V, Zhang J, Fanelli M, Minucci S, **Pelicci PG**, Lazar MA. Aberrant Recruitment of the Nuclear Corepressor Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO. Mol Cell Biol 18:7185-91, 1998.
152. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Ciocce M, Fanelli M, Ruthardt M, Ferrara F, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, **Pelicci PG**. Fusion proteins of the retinoic acid receptor- α recruit histone deacetylase in Promyelocytic Leukaemia. Nature 391:815-8, 1998.
153. Grignani F, Kinsella T, Mencarelli A, Valtieri M, Riganelli D, Grignani F, Lanfrancone L, Peschle C, Nolan GP, **Pelicci PG**. High efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the Green Fluorescence Protein. Cancer Res 58:14-9, 1998.
154. Mozziconacci MJ, Liberatore C, Brunel V, Grignani F, Arnoulet C, Ferrucci PF, Fernandez F, Sainty D, **Pelicci PG**, Birg F, Lafage-Pochitaloff M. In Vitro response to all-trans retinoic acid of Acute Promyelocytic Leukemias with non reciprocal PML/RARa or RARa/PML fusion gene. Genes Chromosome Canc 22:241-50, 1998.
155. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, **Pelicci PG**, Testi R. Caspases Mediate Retinoic Acid-Induced Degradation of the Acute Promyelocytic Leukemia PML/RARa Fusion Protein. Blood 92:2244-51, 1998.
156. Pacini S, Ulivieri C, Di Somma MM, Isacchi A, Lanfrancone L, **Pelicci PG**, Telford JL, Baldari C. Tyrosine 474 on ZAP-70 is required for association with the Shc adaptor and for TCR dependent gene activation. J Biol Chem 273:20487-93, 1998.
157. Paoluzi S, Castagnoli L, Lauro I, Salcini AE, Coda L, Frè S, Confalonieri S, **Pelicci PG**, Di Fiore PP, Cesareni G. Recognition specificity of individual EH domains of mammals and yeast. Embo J 17:6541-50, 1998.
158. Russo D, Regazzi M, Sacchi S, Visani G, Lazzarino M, Avvisati G, **Pelicci PG**, Dastoli G, Grandi C, Iacona I, Candoni A, Grattoni R, Galièni P, Rupoli S, Liberati AM, Maiolo AT. All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. Leukemia 12:449-54, 1998.
159. Regazzi MB, Russo D, Iacona I, Sacchi S, Visani G, Lazzarino M, Avvisati G, **Pelicci PG**, Dastoli G, Grandi C, Spreafico S, Grattoni R, Galièni P, Rupoli S, Maiolo AM, Guerra E, Liberati AM. Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off. Clin Drug Investig 16(1):25-33, 1998.
160. Ruthardt M, Orleth A, Tomassoni L, Puccetti E, Riganelli D, Alcalay M, Mannucci R, Nicoletti I, Grignani F, Fagioli M, **Pelicci PG**. The acute promyelocytic leukemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies. Oncogene 16:1945-53, 1998.

161. Shao W, Fanelli M, Ferrara F, Riccioni R, Rosenauer A, Davison K, Lamph W, Waxman S, **Pelicci PG**, Lo Coco F, Testa U, Gambacorti-Passerini C, Nervi C, Miller WH Jr. AsO₂ as an inducer apoptosis and loss of PML/RAR protein in both retinoid sensitive and resistant APL cells. *J Clin Invest* 90:124-33, 1998.
162. Testa U, Grignani F, Samoggia P, Zanetti C, Riccioni R, Coco FL, Diverio D, Felli N, Passerini CG, Grell M, **Pelicci PG**, Peschle C. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. *J Clin Invest* 101:2278-89, 1998.
163. Testa U, Grignani F, Hassan HJ, Rogaia D, Masciulli R, Gelemtti V, Guerriero R, Macioce G, Liberatore C, Barberi T, Mariani G, **Pelicci PG**, Peschle C. Terminal megakaryocytic differentiation of TF-1 cells is induced by phorbol esters and thrombopoietin and is blocked by expression of PML/RARa fusion protein. *Leukemia* 12:563-70, 1998.

1999

164. Benedetti G, Patoia L, Giglietti A, Alessio M, **Pelicci PG**, Grignani F. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients. *Bone Marrow Transplant* 24:971-9, 1999.
165. Cordell JL, Pulford KAF, Bigerna B, Roncador G, Banham A, Colombo E, **Pelicci PG**, Mason DY, Falini B. Detection of normal and chimaeric nucleophosmin in human cells. *Blood* 93:632-42, 1999.
166. Doria M, Colombo E, Salcini AE, Parslow TG, **Pelicci PG**, Di Fiore PP. The EH-based interaction between Eps15 and Hrb connects the molecular machinery of endocytosis to that of nucleocytoplasmic transport. *J Cell Biol* 147:1379-84, 1999.
167. Falini B, Pulford K, Pucciarini A, Carbone A, De Wolf-Peeters C, Cordell J, Fizzotti M, Santucci A, **Pelicci PG**, Pileri S, Campo E, Ott G, Delsol G, Mason DY. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. *Blood* 94(10):3509-15, 1999.
168. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, **Pelicci PG**, Flenghi L, Martelli MF, Santucci A. ALK⁺ Lymphoma: Clinico-Pathological Findings and Outcome. *Blood* 93:2697-706, 1999.
169. Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C, **Pelicci PG**. Constitutive Degradation of PML/RARa protein through the proteasome pathway mediates retinoic acid resistance. *Blood* 93:1477-81, 1999.
170. Gottifredi V, Pelicci G, Munarizz E, Maione R, **Pelicci PG**, Amati P. Poliovirus large T antigen induces alterations in cytoplasmic signalling pathways involving Shc activation. *J Virol* 73:1427-37, 1999.
171. Grignani F, Gelmetti V, Fanelli M, Rogaia D, De Matteis S, Ferrara FF, Bonci D, Grignani F, Nervi C, **Pelicci PG**. Formation of PML/RARa high molecular weight nuclear complexes through the PML coiled coil region is essential for the PML/RARa-mediated retinoic acid response. *Oncogene* 18:6313-21, 1999.
172. Migliaccio E, Giorgio M, Mele S, Pelicci G, Pandolfi PP, Lanfrancone L, **Pelicci PG**. The p66shc adaptor protein controls oxidative stress response and lifespan in mammals. *Nature* 402(6759):309-13, 1999.
173. Mozziconacci MJ, Liberatore C, Grignani F, Sainty D, **Pelicci PG**, Birg F, Lafage-Pochitaloff M. Atypical of Response to All-Trans Retinoic Acid in a der(5)t(5;17) Acute Promyelocytic Leukemia. *Leukemia* 13(6):862-8, 1999.
174. Pollock JL, Westervelt P, Kurichety AK, **Pelicci PG**, Grisolano JL, Ley JT. A bcr-3 isoform of RARa-PML potentiates the development of PML-RARa driven acute promyelocytic leukemia. *P Natl Acad Sci USA* 96:15103-8, 1999.
175. Casini T, **Pelicci PG**. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. *Oncogene* 18:3235-43, 1999.
176. Torrisi MR, Lotti LV, Belleudi F, Gradini R, Salcini AE, Confalonieri S, **Pelicci PG**, Di Fiore PP. Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization. *Mol Biol Cell* 10:417-34, 1999.

2000

177. Bonati A, Carlo-Stella C, Lunghi P, Albertini R, Pinelli S, Migliaccio E, Sammarelli G, Savoldo B, Tabilio A, Dall'Aglio PP, **Pelicci PG**. Selective expression and constitutive phosphorylation of Src-homology-2 and collagen-homology domains proteins in the CD34+ fraction of chronic myelogenous leukemias. *Cancer Res* 60:728-32, 2000.
178. Di Florio S, Sebastiani C, Fagioli M, Di Ianni M, Alfonsi D, Venditti G, **Pelicci PG**, Tabilio A. Short report: retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and enhanced green fluorescence protein genes in primary T lymphocytes. *Brit J Haematol* 110:903-6, 2000.
179. Grignani F, Valtieri M, Gabbianelli M, Gelmetti V, Botta R, Lucchetti L, Masella B, Morsilli O, Pelosi E, Samoggia P, **Pelicci PG**, Peschle C. PML/RARalpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. *Blood* 96:1531-7, 2000.

180. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, **Pelicci PG**. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. *Mol Cell* 5:811-20, 2000.
181. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, **Pelicci PG**. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. *Nature* 406:207-10, 2000.
182. Plyte S, Majolini MB, Pacini S, Scarpini F, Bianchini C, Lanfrancone L, **Pelicci PG**, Baldari CT. Consecutive activation of the Ras/MAP kinase pathway and enhanced TCR signaling by targeting the shc adaptor to membrane rafts. *Oncogene* 19(12):1529-37, 2000.
183. Santolini E, Puri C, Salcini AE, Gagliani MC, **Pelicci PG**, Tacchetti C, Di Fiore PP. Numb Is an Endocytic Protein. *J Cell Biol* 151(6):1345-52, 2000.
184. Trinei M, Lanfrancone L, Campo E, Pulford K, Mason DY, **Pelicci PG**, Falini B. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. *Cancer Res* 60:793-8, 2000.
185. Vannucchi S, Percario ZA, Chiantore MV, Matarrese P, Chelbi-Alix MK, Fagioli M, **Pelicci PG**, Malorni W, Fiorucci G, Romeo G, and Affabris E. Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells. *Oncogene* 19(44):5041-53, 2000.

2001

186. Conti L, Sipione S, Magrassi L, Bonfanti L, Rigamonti D, Pettrossi V, Peschanski M, Haddad B, **Pelicci PG**, Milanesi G, Pelicci G, Cattaneo E. Shc signaling in differentiating neural progenitor cells. *Nat Neurosci* 4:579-86, 2001.
187. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, Mancini M, **Pelicci PG**, Lo Coco F, Nervi C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. *Cancer Res* 61:2-7, 2001.
188. Galandrini R, Tassi I, Morrone S, Lanfrancone L, **Pelicci PG**, Piccoli M, Frati L, Santoni A. The adaptor protein shc is involved in the negative regulation of NK cell-mediated cytotoxicity. *Eur J Immunol* 7:2016-25, 2001.
189. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, **Pelicci PG**, Heinzl T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. *EMBO J* 20(24):6969-78, 2001.
190. Lunghi P, Tabilio A, Pinelli S, Valmadre G, Ridolo E, Albertini R, Carlo-Stella C, Dall'Aglio PP, **Pelicci PG**, Bonati A. Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. *Hematol J* 2:70-80, 2001.
191. Malabarba MG, Milia E, Faretta M, Zamponi R, **Pelicci PG**, Di Fiore PP. A repertoire library that allows the selection of synthetic SH2s with altered binding specificities. *Oncogene* 20(37):5186-5194, 2001.
192. Nervi C, Borello U, Fazi F, Buffa V, **Pelicci PG**, Cossu G. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. *Cancer Res* 61:1247-9, 2001.
193. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, **Pelicci PG**, Ballabio A. The tripartite motif family identifies cell compartments. *EMBO J* 20:2140-2151, 2001.
194. Salcini AE, Hilliard MA, Croce A, Arbucci S, Luzzi P, Tacchetti C, Daniell L, De Camilli P, **Pelicci PG**, Di Fiore PP, Bazzicalupo P. Nucleotide, Protein The Eps15 C. elegans homologue EHS-1 is implicated in synaptic vesicle recycling. *Nat Cell Biol* 3:755-60, 2001.
195. Zhang J, Hug BA, Huang EY, Chen CW, Gelmetti V, Maccarana M, Minucci S, **Pelicci PG**, Lazar MA. Oligomerization of ETO is obligatory for corepressor interaction. *Mol Cell Biol* 21:156-63, 2001.

2002

196. Bischof O, Kirsh O, Pearson M, Itahana K, **Pelicci PG**, Dejean A. Deconstructing PML-induced premature senescence. *EMBO J* 21(13):3358-69, 2002.
197. Carbone R, Pearson M, Minucci S, **Pelicci PG**. PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. *Oncogene* 21:1633-40, 2002.
198. Colombo E, Marine JC, Danovi D, Falini B, **Pelicci PG**. Nucleophosmin (NPM regulates stability and transcriptional activity of p53. *Nat Cell Biol* 4:529-533, 2002.
199. Contegno F, Cioce M, **Pelicci PG**, Minucci S. Targeting protein inactivation through an oligomerization chain reaction. *P Natl Acad Sci USA* 99(4):1865-9, 2002.

200. Di Croce L, Raker V, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, **Pelicci PG**. Methyltransferase Recruitment and DNA Hypermethylation of Target promoters By an oncogenic Transcription Factor. *Science* 295(5557):1079-82, 2002.
201. La Starza R, Trubia M, Testoni N, Ottaviani E, Belloni E, Crescenzi B, Martelli M, Flandrin G, **Pelicci PG**, Mecucci C. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. *Haematologica* 87(8):789-94, 2002.
202. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, **Pelicci PG**, Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. *EMBO J* 21(10):2383-96, 2002.
203. Migliorini D, Danovi D, Colombo E, Carbone R, **Pelicci PG**, Marine JC. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. *J Biol Chem* 277(9):7318-23, 2002.
204. Migliorini D, Lazzerini E, Danovi D, Jochemsen A, Capillo M, Gobbi A, Helin K, **Pelicci PG**, Marine JC. Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development. *Mol Cell Biol* 22:5527-38, 2002.
205. Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A, Diverio D, Gasparini P, Capillo M, Colombo E, Matteucci C, Contegno F, Lo Coco F, Scanziani E, Gobbi A, **Pelicci PG**. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. *Blood* 100(8):2989-95, 2002.
206. Pelicci G, Troglio F, Bodini A, Melillo RM, Pettirossi V, Coda L, De Giuseppe A, Santoro M, **Pelicci PG**. The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. *Mol Cell Biol* 22(20):7351-63, 2002.
207. Petti MC, Fazi F, Gentile M, Diverio D, De Fabritiis P, De Propriis MS, Fiorini R, Spiriti MA, Padula F, **Pelicci PG**, Nervi C, Lo Coco F. Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. *Blood* 100(3):1065-7, 2002.
208. Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F, Boehrer S, Hoelzer D, Ottmann OG, **Pelicci PG**, Nervi C, Ruthardt M. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. *Cancer Res* 62(23):7050-8, 2002.
209. Puppo F, Griseri P, Fanelli M, Schena F, Romeo G, **Pelicci PG**, Ceccherini I, Ravazzolo R, Patrone G. Cell-line specific chromatin acetylation at the Sox10-Pax3 enhancer site modulates the RET proto-oncogene expression. *FEBS Lett* 523(1-3):123-7, 2002.
210. Tarr PE, Roncarati R, Pelicci G, **Pelicci PG**, D'Adamio L. Tyrosine phosphorylation of the b-amyloid precursor protein cytoplasmic tail promotes interaction with Shc. *J Biol Chem* 277:16798-804, 2002.
211. Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E, Milia E, Padura IM, Raker VA, Maccarana M, Petronilli V, Minucci S, Bernardi P, Lanfrancone L, **Pelicci PG**. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. *Oncogene* 21(24):3872-8, 2002.
212. Ventura A, Luzi L, Pacini S, Baldari CT, **Pelicci PG**. The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter. *J Biol Chem* 277(25):22370-6, 2002.

2003

213. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, Riganelli D, Sebastiani C, Cappelli E, Casciari C, Scirpi MT, Mariano AR, Minardi SP, Luzi L, Muller H, Di Fiore PP, Frosina G, **Pelicci PG**. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. *J Clin Invest* 112(11):1751-61, 2003.
214. Bruno S, Ghiotto F, Fais F, Fagioli M, Luzi L, **Pelicci PG**, Grossi CE, Ciccone E. The PML gene is not involved in the regulation of MHC class I expression in human cell lines. *Blood* 101(9):3514-9, 2003.
215. Di Croce L, **Pelicci PG**. Tumour-associated hypermethylation: silencing E-cadherin expression enhances invasion and metastasis. *Eur J Cancer* 39(4):413-4, 2003.
216. La Starza R, Trubia M, Crescenzi B, Matteucci C, Negrini M, Martelli MF, **Pelicci PG**, Mecucci C. Human homeobox gene HOXC13 is the partner of NUP98 in adult acute myeloid leukemia with t(11;12)(p15;q13). *Gene Chromosome Canc* 36(4):420-3, 2003.
217. Lunghi P, Tabilio A, Dall'Aglio PP, Ridolo E, Carlo-Stella C, **Pelicci PG**, Bonati A. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. *Leukemia* 17(9):1783-93, 2003.
218. Marchesi F, Monestiroli SV, Capillo M, Gobbi A, Minucci S, **Pelicci PG**, Scanziani E. Eosinophilic crystals as a distinctive morphologic feature of a hyaline droplet nephropathy in a mouse model of acute myelogenous leukaemia. *J Vet Med A Physiol Pathol Clin Med* 50(2):103-7, 2003.

219. Masseroli M, Cerveri P, **Pelicci PG**, Alcalay M. GAAS: Gene Array Analyzer Software for management, analysis and visualization of gene expression data. *Bioinformatics* 19(6), 774-775, 2003.
220. Napoli C, Martin-Padura I, de Nigris F, Giorgio M, Mansueto G, Somma P, Condorelli M, Sica G, De Rosa G, **Pelicci PG**. Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. *Proc Natl Acad Sci U S A* 100(4):2112-6, 2003.
221. Scherer SW, Cheung J, MacDonald JR, Osborne LR, Nakabayashi K, Herbrick JA, Carson AR, Parker-Katiraei L, Skaug J, Khaja R, Zhang J, Hudek AK, Li M, Haddad M, Duggan GE, Fernandez BA, Kanematsu E, Gentles S, Christopoulos CC, Choufani S, Kwasnicka D, Zheng XH, Lai Z, Nusskern D, Zhang Q, Gu Z, Lu F, Zeesman S, Nowaczyk MJ, Teshima I, Chitayat D, Shuman C, Weksberg R, Zackai EH, Grebe TA, Cox SR, Kirkpatrick SJ, Rahman N, Friedman JM, Heng HH, **Pelicci PG**, Lo Coco F, Belloni E, Shaffer LG, Pober B, Morton CC, Gusella JF, Bruns GA, Korf BR, Quade BJ, Ligon AH, Ferguson H, Higgins AW, Leach NT, Herrick SR, Lemyre E, Farra CG, Kim HG, Summers AM, Gripp KW, Roberts W, Szatmari P, Winsor EJ, Grzeschik KH, Teebi A, Minassian BA, Kere J, Armengol L, Pujana MA, Estivill X, Wilson MD, Koop BF, Tosi S, Moore GE, Boright AP, Zlotorynski E, Kerem B, Kroisel PM, Petek E, Oscier DG, Mould SJ, Dohner H, Dohner K, Rommens JM, Vincent JB, Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC. Human chromosome 7: DNA sequence and biology. *Science* 300(5620):767-72, 2003.
222. Segalla S, Rinaldi L, Kilstrup-Nielsen C, Badaracco G, Minucci S, **Pelicci PG**, Landsberger N. Retinoic acid receptor alpha fusion to PML affects its transcriptional and chromatin-remodeling properties. *Mol Cell Biol* 23(23):8795-808, 2003.

2004

223. Belloni E, Trubia M, Mancini M, Derme V, Nanni M, Lahortiga I, Riccioni R, Confalonieri S, Lo-Coco F, Di Fiore PP, **Pelicci PG**. A New Complex Rearrangement Involving the ETV6, LOC115548, and MN1 Genes in a Case of Acute Myeloid Leukemia. *Gene Chromosome Canc* 41:272-277, 2004.
224. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, De Graaf P, Francoz S, Gasparini P, Gobbi A, Helin K, **Pelicci PG**, Jochemsen AG, Marine JC. Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity. *Mol Cell Biol* 24(13):5835-43, 2004.
225. Fanelli M, Fantozzi A, De Luca P, Caprodossi S, Matsuzawa SI, Lazar MA, **Pelicci PG**, Minucci S. The coiled-coil domain is the structural determinant for SIAH-mediated degradation of PML and other TRIM proteins by the proteasome. *J Biol Chem* 279(7):5374-5379, 2004.
226. Francia P, delli Gatti C, Bachschmid M, Martin-Padura I, Savoia C, Migliaccio E, **Pelicci PG**, Schiavoni M, Luscher TF, Volpe M, Cosentino F. Deletion of p66shc gene protects against age-related endothelial dysfunction. *Circulation* 110(18):2889-95, 2004.
227. Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, Pruneri G, Viale G, Appella E, **Pelicci PG**, Minucci S. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. *EMBO J* 23(5):1144-54, 2004.
228. Lahortiga I, Agirre X, Belloni E, Vazquez I, Larrayoz MJ, Gasparini P, Coco FL, **Pelicci PG**, Calasanz MJ, Odero MD. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. *Oncogene* 23(1):311-6, 2004.
229. Mandala M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, **Pelicci PG**, Biffi R, Orsi F, Cinieri S, Goldhirsch A. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. *Ann Oncol* 15(4):590-3, 2004.
230. Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D, Martin-Padura I, Pelliccia G, Trinei M, Bono M, Puri C, Tacchetti C, Ferrini M, Mannucci R, Nicoletti I, Lanfrancone L, Giorgio M, **Pelicci PG**. The Life Span Determinant p66Shc Localizes to Mitochondria Where It Associates with Mitochondrial Heat Shock Protein 70 and Regulates Trans-membrane Potential. *J Biol Chem* 279(24):25689-95, 2004.
231. Pacini S, Pellegrini M, Migliaccio E, Patrussi L, Olivieri C, Ventura A, Carraro F, Naldini A, Lanfrancone L, **Pelicci PG**, Baldari CT. p66SHC Promotes Apoptosis and Antagonizes Mitogenic Signaling in T Cells. *Mol Cell Biol* 24(4):1747-57, 2004.
232. Transidico P, Bianchi M, Capra M, **Pelicci PG**, Faretta M. From Cells to Tissues: Fluorescence Confocal Microscopy in the Study of Histological Samples. *Microscopy Res Techniq* 64, 89-95, 2004.
233. Troglio F, Echart C, Gobbi A, Pawson T, **Pelicci PG**, De Simoni MG, Pelicci G. The Rai (Shc C) adaptor protein regulates the neuronal stress response and protects against cerebral ischemia. *Proc Natl Acad Sci USA* 101(43):15476-81, 2004.
234. Ventura A, Maccarana M, Raker VA, **Pelicci PG**. A cryptic targeting signal induces isoform-specific localization of p46Shc to mitochondria. *J Biol Chem* 276:2299-2306, 2004.

235. Zaccagnini G, Martelli F, Fasanaro P, Magenta A, Gaetano C, Di Carlo A, Biglioli P, Giorgio M, Martin-Padura I, **Pelicci PG**, Capogrossi MC. p66ShcA modulates tissue response to hindlimb ischemia. *Circulation* 109(23):2917-23, 2004.

2005

236. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, Meani N, Diverio D, Bernard L, Tizzoni L, Volorio S, Luzi L, Colombo E, Lo Coco F, Mecucci C, Falini B, **Pelicci PG**. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. *Blood* 106(3):899-902, 2005.
237. Belloni E, Trubia M, Gasparini P, Micucci C, Tapinassi C, Confalonieri S, Nuciforo P, Martino B, Lo Coco F, **Pelicci PG**, Di Fiore PP. 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. *Gene Chromosome Canc* 42(3):320-5, 2005.
238. Brenner C, Deplus R, Didelot C, Loriot A, Vire E, De Smet C, Gutierrez A, Danovi D, Bernard D, Boon T, **Pelicci PG**, Amati B, Kouzarides T, de Launoit Y, Di Croce L, Fuks F. Myc represses transcription through recruitment of DNA methyltransferase corepressor. *EMBO J* 24(2):336-46, 2005.
239. Caprodossi S, Pedinotti M, Amantini C, Santoni G, Minucci S, **Pelicci PG**, Fanelli M. Differentiation Response of Acute Promyelocytic Leukemia Cells and PML/RAR α Leukemogenic Activity Studies by Real-Time RT-PCR. *Mol Biotechnol* 30(3):231-8, 2005.
240. Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R, Marine JC, Helin K, Falini B, **Pelicci PG**. Nucleophosmin Is Required for DNA Integrity and p19Arf Protein Stability. *Mol Cell Biol* 25(20):8874-86, 2005.
241. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettrossi V, Saglio G, Mandelli F, Lo Coco F, **Pelicci PG**, Martelli MF; GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *New Engl J Med* 352(3):254-66, 2005.
242. Fazi F, Travaglini L, Carotti D, Palitti F, Diverio D, Alcalay M, McNamara S, Miller WH, Coco FL, **Pelicci PG**, Nervi C. Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. *Oncogene* 24(11):1820-30, 2005.
243. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia P, Luzi L, Minucci S, Marcaccio M, Pinton P, Rizzuto R, Bernardi P, Paolucci F, **Pelicci PG**. Electron Transfer between Cytochrome c and p66Shc Generates Reactive Oxygen Species that Trigger Mitochondrial Apoptosis. *Cell* 122:1-13, 2005.
244. Gorletta TA, Gasparini P, D'Elios MM, Trubia M, **Pelicci PG**, Di Fiore PP. Frequent loss of heterozygosity without loss of genetic material in acute myeloid leukemia with a normal karyotype. *Gene Chromosome Canc* 44(3):334-7, 2005.
245. Graiani G, Lagrasta C, Migliaccio E, Spillmann F, Meloni M, Madeddu P, Quaini F, Padura IM, Lanfrancone L, **Pelicci PG**, Emanuelli C. Genetic Deletion of the p66Shc Adaptor Protein Protects From Angiotensin II-Induced Myocardial Damage. *Hypertension* 46(2):433-40, 2005.
246. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, **Pelicci PG**. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. *Nat Med* 11(1):71-6, 2005. [Erratum in: *Nat Med* 11(2):233, 2005].
247. Kindle KB, Troke PJ, Collins HM, Matsuda S, Bossi D, Bellodi C, Kalkhoven E, Salomoni P, **Pelicci PG**, Minucci S, Heery DM. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function. *Mol Cell Biol* 25(3):988-1002, 2005.
248. Lahortiga I, Vazquez I, Belloni E, Roman JP, Gasparini P, Novo FJ, Zudaire I, **Pelicci PG**, Hernandez JM, Calasanz MJ, Otero MD. FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome. *Hum Genet* 116(6):476-85, 2005.
249. Lunghi P, Tabilio A, Lo Coco F, **Pelicci PG**, Bonati A. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. *Leukemia* 19(2):234-44, 2005.
250. Martoriati A, Doumont G, Alcalay M, Bellefroid E, **Pelicci PG**, Marine JC. dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53. *Oncogene* 24(8):1461-6, 2005.
251. Meani N, Minardi S, Licciulli S, Gelmetti V, Coco FL, Nervi C, **Pelicci PG**, Muller H, Alcalay M. Molecular signature of retinoic acid treatment in acute promyelocytic leukemia. *Oncogene* 24(20):3358-68, 2005.
252. Patrussi L, Savino MT, Pellegrini M, Paccani SR, Migliaccio E, Plyte S, Lanfrancone L, **Pelicci PG**, Baldari CT. Cooperation and selectivity of the two Grb2 binding sites of p52Shc in T-cell antigen receptor signaling to Ras family GTPases and Myc-dependent survival. *Oncogene* 24(13):2218-28, 2005.

253. Pilatrinò C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, Familiari U, Cappia S, **Pelicci PG**, Lo Coco F, Saggio G, Guerrasio A. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. *Cancer* 104(1):101-9, 2005.
254. Ronzoni S, Faretta M, Ballarini M, **Pelicci PG**, Minucci S. New method to detect histone acetylation levels by flow cytometry. *Cytom part A* 66(1):52-61, 2005.
255. Caprodossi S, Galluzzi L, Biagetti S, Della Chiara G, **Pelicci PG**, Magnani M, Fanelli M. In vitro inhibition of promyelocytic leukemia/retinoic acid receptor-alpha (PML/RARalpha) expression and leukemogenic activity by DNA/LNA chimeric antisense oligos. *Oncol Res* 16(3):157-66, 2005.
-
- 2006
256. Berry A, Capone F, Giorgio M, **Pelicci PG**, de Kloet ER, Alleva E, Minghetti L, Cirulli F. Deletion of the life span determinant p66(Shc) prevents age-dependent increases in emotionality and pain sensitivity in mice. *Exp Gerontol* 42(1-2):37-45, 2006.
257. Carbone R, Botrugno OA, Ronzoni S, Insinga A, Di Croce L, **Pelicci PG**, Minucci S. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. *Mol Cell Biol* 26(4):1288-96, 2006.
258. Carbone R, Marangi I, Zanardi A, Giorgetti L, Chierici E, Berlanda G, Podesta A, Fiorentini F, Bongiorno G, Piseri P, **Pelicci PG**, Milani P. Biocompatibility of cluster-assembled nanostructured TiO₂ with primary and cancer cells. *Biomaterials* 27(17):3221-9, 2006.
259. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Aloe Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, **Pelicci PG**, Nervi C. Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. *Cancer Res* 66(17):8903-11, 2006.
260. Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, **Pelicci PG**. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. *Cancer Res* 66(6):3044-50, 2006.
261. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garrè M, Nuciforo PG, Bensimon A, Maestro R, **Pelicci PG**, d'Adda di Fagagna F. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature* 444(7119):638-42, 2006.
262. Falini B, Bigerna B, Pucciarini A, Tiacci E, Mecucci C, Morris SW, Bolli N, Rosati R, Hanissian S, Ma Z, Sun Y, Colombo E, Arber DA, Pacini R, La Starza R, Galletti BV, Liso A, Martelli MP, Diverio D, **Pelicci PG**, Coco FL, Martelli MF. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. *Leukemia* 20(2):368-371, 2006 -[Erratum in: *Leukemia* 20(7):1330, 2006. Coco, FL (corrected to Lo Coco, F); Galletti, BV (corrected to Verducci Galletti, B)].
263. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, Diverio D, Nicoletti I, Pacini R, Tabarrini A, Verducci Galletti B, Mannucci R, Roti G, Rosati R, Specchia G, Liso A, Tiacci E, Alcalay M, Luzi L, Volorio S, Bernard L, Guarini A, Amadori S, Mandelli F, Pane F, Lo Coco F, Saggio G, **Pelicci PG**, Martelli MF, Mecucci C. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. *Blood* 108(6):1999-2005, 2006.
264. Marchesi F, Minucci S, **Pelicci PG**, Gobbi A, Scanziani E. Immunohistochemical Detection of Ym1/Ym2 Chitinase-like Lectins Associated with Hyalinosis and Polypoid Adenomas of the Transitional Epithelium in a Mouse with Acute Myeloid Leukemia. *Vet Pathol* 43(5):773-6, 2006.
265. Mariano AR, Colombo E, Luzi L, Martinelli P, Volorio S, Bernard L, Meani N, Bergomas R, Alcalay M, **Pelicci PG**. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal. *Oncogene* 25(31):4376-80, 2006.
266. Menini S, Amadio L, Oddi G, Ricci C, Pesce C, Pugliese F, Giorgio M, Migliaccio E, **Pelicci PG**, Iacobini C, Pugliese G. Deletion of p66Shc Longevity Gene Protects Against Experimental Diabetic Glomerulopathy by Preventing Diabetes-Induced Oxidative Stress. *Diabetes* 55(6), 1642-50, 2006.
267. Orsini F, Moroni M, Contursi C, Yano M, **Pelicci PG**, Giorgio M, Migliaccio E. Regulatory effects of the mitochondrial energetic status on mitochondrial p66(Shc). *Biol Chem*. 387(10-11):1405-10, 2006.
268. Pellegrini M, Finetti F, Petronilli V, Ulivieri C, Giusti F, Lupetti P, Giorgio M, **Pelicci PG**, Bernardi P, Baldari CT. p66SHC promotes T cell apoptosis by inducing mitochondrial dysfunction and impaired Ca²⁺ homeostasis. *Cell Death Differ* 14(2):338-47, 2006.
269. Pezzicoli A, Ulivieri C, Capitani N, Ventura A, **Pelicci PG**, Baldari CT. Expression in T-cells of the proapoptotic protein p66SHC is controlled by promoter demethylation. *Biochem Biophys Res Co* 349(1):322-8, 2006.
270. Rota M, LeCapitaine N, Hosoda T, Boni A, De Angelis A, Padin-Iruegas ME, Esposito G, Vitale S, Urbanek K, Casarsa C, Giorgio M, Luscher TF, **Pelicci PG**, Anversa P, Leri A, Kajstura J. Diabetes promotes cardiac stem cell

aging and heart failure, which are prevented by deletion of the p66shc gene. *Circ Res* 99(1):42-52, 2006.

271. Trinei M, Berniakovich I, **Pelicci PG**, Giorgio M. Mitochondrial DNA copy number is regulated by cellular proliferation: A role for Ras and p66(Shc). *BBA - Bioenergetics* 1757(5-6):624-30, 2006.
272. Trubia M, Albano F, Cavazzini F, Cambrin GR, Quarta G, Fabbiano F, Ciambelli F, Magro D, Hernandez JM, Mancini M, Diverio D, **Pelicci PG**, Coco FL, Mecucci C, Specchia G, Rocchi M, Liso V, Castoldi G, Cuneo A. Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia. *Leukemia* 20(1):48-54, 2006.
273. Villa R, Morey L, Raker VA, Buschbeck M, Gutierrez A, De Santis F, Corsaro M, Varas F, Bossi D, Minucci S, **Pelicci PG**, Di Croce L. The methyl-CpG binding protein MBD1 is required for PML-RAR{alpha} function. *Proc Natl Acad Sci USA* 103(5):1400-5, 2006.

2007

274. Berry A, Greco A, Giorgio M, **Pelicci PG**, de Kloet R, Alleva E, Minghetti L, Cirulli F. Deletion of the lifespan determinant p66(Shc) improves performance in a spatial memory task, decreases levels of oxidative stress markers in the hippocampus and increases levels of the neurotrophin BDNF in adult mice. *Exp Gerontol* 43:200-8, 2007.
275. Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, Hersberger M, Tanner FC, **Pelicci P**, Volpe M, Anversa P, Luscher TF, Cosentino F. Genetic deletion of p66Shc adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. *Proc Natl Acad Sci U S A* 104(12):5217-22, 2007.
276. Carbone R, Giorgetti L, Zanardi A, Marangi I, Chierici E, Bongiorno G, Fiorentini F, Faretta M, Piseri P, **Pelicci PG**, Milani P. Retroviral microarray-based platform on nanostructured TiO(2) for functional genomics and drug discovery. *Biomaterials* 28(13):2244-53, 2007.
277. Carraro F, Pucci A, Pellegrini M, **Pelicci PG**, Baldari CT, Naldini A. p66Shc is involved in promoting HIF-1alpha accumulation and cell death in hypoxic T cells. *J Cell Physiol* 211(2):439-47, 2007.
278. Fagiani E, Giardina G, Luzi L, Cesaroni M, Quarto M, Capra M, Germano G, Bono M, Capillo M, **Pelicci P**, Lanfrancone L. RalP, a New Member of the Src Homology and Collagen Family, Regulates Cell Migration and Tumor Growth of Metastatic Melanomas. *Cancer Res* 67(7):3064-73, 2007.
279. Fazi F, Zardo G, Gelmetti V, Travaglini L, Ciolfi A, Di Croce L, Rosa A, Bozzoni I, Grignani F, Lo-Coco F, **Pelicci PG**, Nervi C. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. *Blood* 109(10):4432-40, 2007.
280. Franceschi C, Bezrukov V, Blanché H, Bolund L, Christensen K, de Benedictis G, Deiana L, Gonos E, Hervonen A, Yang H, Jeune B, Kirkwood TB, Kristensen P, Leon A, **Pelicci PG**, Peltonen L, Poulain M, Rea IM, Remacle J, Robine JM, Schreiber S, Sikora E, Slagboom PE, Spazzafumo L, Stazi MA, Toussaint O, Vaupel JW. Genetics of healthy aging in Europe: the EU-integrated project GEHA (Genetics of Healthy Aging). *Ann N Y Acad Sci* 1100:21-45, 2007.
281. Marinelli A, Bossi D, **Pelicci PG**, Minucci S. A redundant oncogenic potential of the retinoic receptor (RAR) alpha, beta and gamma isoforms in acute promyelocytic leukemia. *Leukemia* 21(4):647-50, 2007.
282. Menini S, Iacobini C, Ricci C, Oddi G, Pesce C, Pugliese F, Block K, Abboud HE, Giorgio M, Migliaccio E, **Pelicci PG**, Pugliese G. Ablation of the gene encoding p66(Shc) protects mice against AGE-induced glomerulopathy by preventing oxidant-dependent tissue injury and further AGE accumulation. *Diabetologia* 50:1997-2007, 2007.
283. Patrussi L, Ulivieri C, Lucherini OM, Rossi Paccani S, Gamberucci A, Lanfrancone L, **Pelicci PG**, Baldari CT. p52SHC is required for CXCR4-dependent signaling and chemotaxis in T-cells. *Blood* 110:1730-8, 2007.
284. Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M, Contursi C, Minucci S, Mantovani F, Wieckowski MR, Del Sal G, **Pelicci PG**, Rizzuto R. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. *Science* 315(5812):659-63, 2007.
285. Shing DC, Trubia M, Marchesi F, Radaelli E, Belloni E, Tapinassi C, Scanziani E, Mecucci C, Crescenzi B, Lahortiga I, Odero MD, Zardo G, Gruszka A, Minucci S, Di Fiore PP, **Pelicci PG**. Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. *J Clin Invest* 117:3696-707, 2007.
286. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Vire E, Nomdedeu JF, Jenuwein T, **Pelicci PG**, Minucci S, Fuks F, Helin K, Di Croce L. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. *Cancer Cell* 11(6):513-25, 2007.
287. Zaccagnini G, Martelli F, Magenta A, Cencioni C, Fasanaro P, Nicoletti C, Biglioli P, **Pelicci PG**, Capogrossi MC. p66ShcA and oxidative stress modulate myogenic differentiation and skeletal muscle regeneration after hindlimb ischemia. *J Biol Chem* 282:31453-9, 2007.
288. Zanardi A, Giorgetti L, Botrugno OA, Minucci S, Milani P, **Pelicci PG**, Carbone R. Immunocell-array for molecular dissection of multiple signaling pathways in mammalian cells. *Mol Cell Proteomics* 6:939-947, 2007.

2008

289. Berniakovich I, Trinei M, Stendardo M, Migliaccio E, Minucci S, Bernardi P, **Pelicci PG**, Giorgio M. p66Shc-generated oxidative signal promotes fat accumulation. *J Biol Chem* 283:34283-93, 2008.
290. Bonetti P, Davoli T, Sironi C, Amati B, **Pelicci PG**, Colombo E. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. *J Cell Biol* 182:19-26, 2008.
291. Cesaroni M, Cittaro D, Brozzi A, **Pelicci PG**, Luzi L. CARPET: a web-based package for the analysis of ChIP-chip and expression tiling data. *Bioinformatics* 24:2918-20, 2008.
292. Di Micco R, Cicalese A, Fumagalli M, Dobreva M, Verrecchia A, **Pelicci PG**, di Fagagna FD. DNA damage response activation in mouse embryonic fibroblasts undergoing replicative senescence and following spontaneous immortalization. *Cell Cycle* 7:3601-6, 2008.
293. Fanelli M, Caprodossi S, Ricci-Vitiani L, Porcellini A, Tomassoni-Ardori F, Amatori S, Andreoni F, Magnani M, De Maria R, Santoni A, Minucci S, **Pelicci PG**. Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. *Oncogene* 27:358-65, 2008.
294. Finetti F, Pellegrini M, Ulivieri C, Savino MT, Paccagnini E, Ginanneschi C, Lanfrancone L, **Pelicci PG**, Baldari CT. The proapoptotic and antimitogenic protein p66SHC acts as a negative regulator of lymphocyte activation and autoimmunity. *Blood* 111:5017-27, 2008.
295. Gardini A, Cesaroni M, Luzi L, Okumura AJ, Biggs JR, Minardi SP, Venturini E, Zhang DE, **Pelicci PG**, Alcalay M. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. *PLoS Genet* 4(11):e1000275, 2008.
296. Gorello P, La Starza R, Brandimarte L, Trisolini SM, Pierini V, Crescenzi B, Limongi MZ, Nanni M, Belloni E, Tapinassi C, Gerbino E, Martelli MF, Foà R, Meloni G, **Pelicci PG**, Mecucci C. A PDGFRB-positive acute myeloid malignancy with a new involving the ERC1 gene. *Leukemia* 22:216-8, 2008.
297. Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M, Testoni N, Bardi A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M, Amadori S, Mandelli F, **Pelicci PG**, Mecucci C, Falini B, Saglio G. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. *Haematologica* 93:1017-24, 2008.
298. Martin-Padura I, de Nigris F, Migliaccio E, Mansueto G, Minardi S, Rienzo M, Lerman LO, Stendardo M, Giorgio M, De Rosa G, **Pelicci PG**, Napoli C. p66(Shc) Deletion Confers Vascular Protection in Advanced Atherosclerosis in Hypercholesterolemic Apolipoprotein E Knockout Mice. *Endothelium* 15:276-87, 2008.
299. Ronzoni S, Faretta M, Ballarini M, **Pelicci PG**, Minucci S. Assessment of histone acetylation levels in relation to cell cycle phase. *Curr Protoc Cytom* Chapter 7: Unit 7.3, 2008.
300. Tapinassi C, Gerbino E, Malazzi O, Micucci C, Gasparini P, Najera MJ, Calasanz MJ, Odero MD, **Pelicci PG**, Belloni E. A new A new dic(7;1.2)(p12.21;p12.2) chromosome aberration in a case of acute myeloid leukemia. *Cancer Genet Cytogenet* 185:102-5, 2008.
301. Wanzel M, Russ AC, Kleine-Kohlbrecher D, Colombo E, **Pelicci PG**, Eilers M. A ribosomal protein L23-nucleophosmin circuit coordinates Miz1 function with cell growth. *Nat Cell Biol* 10:1051-61, 2008.
-
- 2009
302. Amatori S, Papalini F, Lazzarini R, Donati B, Bagaloni I, Rippon MR, Procopio A, **Pelicci PG**, Catalano A, Fanelli M. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. *Lung Cancer* 66:184-190, 2009.
303. Carpi A, Menabò R, Kaludercic N, **Pelicci P**, Di Lisa F, Giorgio M. The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. *Biochim Biophys Acta* 1787(7):774-80, 2009.
304. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Brisken C, Minucci S, Di Fiore PP, **Pelicci PG**. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. *Cell* 138:1083-95, 2009.
305. Galletti M, Riccardo S, Parisi F, Lora C, Saqçena MK, Rivas L, Wong B, Serra A, Serras F, Grifoni D, **Pelicci P**, Jiang J, Bellosa P. Identification of Domains Responsible for Ubiquitin-dependent Degradation of dMyc by GSK3{beta} and CKI kinases. *Mol Cell Biol* 29(12):3424-34, 2009.
306. Gargiulo G, Levy S, Bucci G, Romanenghi M, Fornasari L, Beeson KY, Goldberg SM, Cesaroni M, Ballarini M, Santoro F, Bezman N, Frigè G, Gregory PD, Holmes MC, Strausberg RL, **Pelicci PG**, Urnov FD, Minucci S. NA-Seq: a discovery tool for the analysis of chromatin structure and dynamics during differentiation. *Dev Cell* 16:466-81, 2009.
307. Gerbino E, Tapinassi C, Malazzi O, Micucci C, Calasanz MJ, Beltran-Heredia JM, Gasparini P, Odero MD, **Pelicci PG**, Belloni E. A novel t(7;13)(p12;q33 approximately q34) in AML-M2. *Cancer Genet Cytogenet* 195:198-200, 2009.

308. Marinelli A, Bossi D, **Pelicci PG**, Minucci S. Redundant function of retinoic acid receptor isoforms in leukemogenesis unravels a prominent function of genome topology and architecture in the selection of mutagenic events in cancer. *Leukemia* 23, 417-9, 2009.
309. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nolè F, Munzone E, Salmaggi A, Goldhirsch A, **Pelicci PG**, Testori A. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. *Br J Cancer* 100:28-36, 2009.
310. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, Ronchini C, Ronzoni S, Muradore I, Monestiroli S, Gobbi A, Alcalay M, Minucci S, **Pelicci PG**. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. *Nature* 457(7225):51-6, 2009.

2010

311. Berry A, Carnevale D, Giorgio M, **Pelicci PG**, de Kloet ER, Alleva E, Minghetti L, Cirulli F. Greater resistance to inflammation at adulthood could contribute to extended life span of p66(Shc^{-/-}) mice. *Exp Gerontol* 45:343-50, 2010.
312. Capitani N, Lucherini OM, Sozzi E, Ferro M, Giommoni N, Finetti F, De Falco G, Cencini E, Raspadori D, **Pelicci PG**, Lauria F, Forconi F, Baldari CT. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. *Blood* 115:3726-36, 2010.
313. Fadini GP, Albiero M, Menegazzo L, Boscaro E, Pagnin E, Iori E, Cosma C, Lapolla A, Pengo V, Stendardo M, Agostini C, **Pelicci PG**, Giorgio M, Avogaro A. The redox enzyme p66Shc contributes to diabetes and ischemia-induced delay in cutaneous wound healing. *Diabetes* 59:2306-14, 2010.
314. Fanelli M, Amatori S, Barozzi I, Soncini M, Dal Zuffo R, Bucci G, Capra M, Quarto M, Dellino GI, Mercurio C, Alcalay M, Viale G, **Pelicci PG**, Minucci S. Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. *Proc Natl Acad Sci USA* 107(50):21535-40, 2010.
315. Gruszka AM, Lavorgna S, Irno Consalvo M, Ottone T, Martinelli C, Cinquanta M, Ossolengo G, Pruneri G, Buccisano F, Divona M, Cedrone M, Ammatuna E, Venditti A, de Marco A, Lo-Coco F, **Pelicci PG**. A monoclonal antibody against mutated nucleophosmin1 for the molecular diagnosis of acute myeloid leukemias. *Blood* 116:2096-102, 2010.
316. Marenzi G, Giorgio M, Trinei M, Moltrasio M, Ravagnani P, Cardinale D, Ciceri F, Cavallero A, Veglia F, Fiorentini C, Cipolla CM, Bartorelli AL, **Pelicci P**. Circulating cytochrome c as potential biomarker of impaired reperfusion in ST-segment elevation acute myocardial infarction. *Am J Cardiol* 106(10):1443-9, 2010.
317. Naldini A, Morena E, Pucci A, Pellegrini M, Baldari CT, **Pelicci PG**, Presta M, Ribatti D, Carraro F. The adaptor protein p66shc is a positive regulator in the angiogenic response induced by hypoxic T cells. *J Leukoc Biol* 87:365-9, 2010.
318. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, **Pelicci PG**, Di Fiore PP. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. *Cell* 140:62-73, 2010.
319. Pedranzini L, Mottadelli F, Ronzoni S, Rossella F, Ferracin M, Magnani I, Roversi G, Colapietro P, Negrini M, **Pelicci PG**, Larizza L. Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34(+)/38(-) compartment. *Leuk Res* 34:1287-95, 2010.
320. Titta L, Trinei M, Stendardo M, Berniakovich I, Petroni K, Tonelli C, Riso P, Porrini M, Minucci S, **Pelicci PG**, Rapisarda P, Recupero GR, Giorgio M. Blood orange juice inhibits fat accumulation in mice. *Int J Obes* 34:578-88, 2010.
321. Tomilov AA, Bicocca V, Schoenfeld RA, Giorgio M, Migliaccio E, Ramsey JJ, Hagopian K, **Pelicci PG**, Cortopassi GA. Decreased superoxide production in macrophages of long-lived p66Shc-knockout mice. *J Biol Chem* 285:1153-65, 2010

2011

322. Belloni E, Shing D, Tapinassi C, Viale A, Mancuso P, Malazzi O, Gerbino E, Dall'olio V, Egurbide I, Odero MD, Bertolini F, **Pelicci PG**. In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels. *Leukemia* 25:733-6, 2011.
323. Belloni E, Veronesi G, Micucci C, Javan S, Minardi SP, Venturini E, Maisonneuve P, Volorio S, Riboni M, Bellomi M, Scanagatta P, Taliento G, Pelosi G, Pece S, Spaggiari L, **Pelicci PG**. Genomic characterization of asymptomatic CT-detected lung cancers. *Oncogene* 30(9):1117-26, 2011.
324. Gadad SS, Senapati P, Syed SH, Rajan RE, Shandilya J, Swaminathan V, Chatterjee S, Colombo E, Dimitrov S, **Pelicci PG**, Ranga U, Kundu TK. The Multifunctional Protein Nucleophosmin (NPM1) Is a Human Linker Histone H1 Chaperone. *Biochemistry*, 50(14):2780-9, 2011.

325. Lunardi A, Gaboli M, Giorgio M, Rivi R, Bygrave A, Antoniou M, Drabek D, Dzierzak E, Fagioli M, Salmena L, Botto M, Cordon-Cardo C, Luzzatto L, **Pelicci PG**, Grosveld F, Pandolfi PP. A Role for PML in Innate Immunity. *Genes Cancer* 2(1):10-9, 2011.
326. Martinelli P, Bonetti P, Sironi C, Pruneri G, Fumagalli C, Raviele PR, Volorio S, Pileri S, Chiarle R, McDuff FK, Tusi BK, Turner SD, Inghirami G, **Pelicci PG**, Colombo E. The lymphoma-associated NPM-ALK oncogene elicits a p16INKa/pRb-dependent tumour-suppressive pathway. *Blood* 117(24):6617-26, 2011.
327. Occhionorelli M, Santoro F, Pallavicini I, Gruszka A, Moretti S, Bossi D, Viale A, Shing D, Ronzoni S, Muradore I, Soncini M, Pruneri G, Rafaniello P, Viale G, **Pelicci PG**, Minucci S. The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. *Leukemia*, 25(5):814-20, 2011.
328. Pasi CE, Dereli-Öz A, Negrini S, Friedli M, Fragola G, Lombardo A, Van Houwe G, Naldini L, Casola S, Testa G, Trono D, **Pelicci PG**, Halazonetis TD. Genomic instability in induced stem cells. *Cell Death Differ* 18(5):745-53, 2011.
329. Pesaresi MG, Amori I, Giorgi C, Ferri A, Fiorenzo P, Gabanella F, Salvatore AM, Giorgio M, **Pelicci PG**, Pinton P, Carri MT, Cozzolino M. Mitochondrial redox signaling by p66Shc mediates ALS-like disease through Rac1 inactivation. *Hum Mol Genet* 20(21):4196-208, 2011.
330. Tomilov AA, Ramsey JJ, Hagopian K, Giorgio M, Kim KM, Lam A, Migliaccio E, Lloyd KC, Berniakovich I, Prolla TA, **Pelicci PG**, Cortopassi GA. The Shc locus regulates insulin signaling and adiposity in mammals. *Aging Cell* 10(1):55-65, 2011.
331. Ulivieri C, Fanigliulo D, Masi G, Savino MT, Gamberucci A, **Pelicci PG**, Baldari CT. p66Shc Is a Negative Regulator of Fc{varepsilon}RI-Dependent Signaling in Mast Cells. *J Immunol* 186(9):5095-106, 2011.

2012

332. Beltrami E, Valtorta S, Moresco R, Marcu R, Belloli S, Fassina A, Fazio F, **Pelicci PG**, Giorgio M. The p53-p66Shc apoptotic pathway is dispensable for tumor suppression whereas the p66Shc-generated oxidative stress initiates tumorigenesis. *Curr Pharm Des* 2012 Oct 18. [Epub ahead of print]
333. Berry A, Amrein I, Nötzli S, Lazic SE, Bellisario V, Giorgio M, **Pelicci PG**, Alleva E, Lipp HP, Cirulli F. Sustained hippocampal neurogenesis in females is amplified in P66(Shc-/-) mice: An animal model of healthy aging. *Hippocampus* 22(12):2249-59, 2012.
334. Breccia M, Mazzarella L, Bagnardi V, Disalvatore D, Loglisci G, Cimino G, Testi AM, Avvisati G, Petti MC, Minotti C, Latagliata R, Foà R, **Pelicci PG**, Lo-Coco F. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. *Blood* 119(1):49-54, 2012.
335. Capitani N, Patrussi L, Trentin L, Lucherini OM, Cannizzaro E, Migliaccio E, Frezzato F, Gattazzo C, Forconi F, **Pelicci PG**, Semenzato G, Baldari CT. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. *Blood* 120(22):4391-9, 2012.
336. Castelli M, Pieroni S, Brunacci C, Piobbico D, Bartoli D, Bellet MM, Colombo E, **Pelicci PG**, Della Fazio MA, Servillo G. Hepatocyte odd protein shuttling (HOPS) is a bridging protein in the nucleophosmin-p19(Arf) network. *Oncogene* 2012 Aug 13. doi: 10.1038/onc.2012.353. [Epub ahead of print]
337. Giorgio M, Berry A, Berniakovich I, Poletaeva I, Trinei M, Stendardo M, Hagopian K, Ramsey JJ, Cortopassi G, Migliaccio E, Nötzli S, Amrein I, Lipp HP, Cirulli F, **Pelicci PG**. The p66(Shc) knocked out mice are short lived under natural condition. *Aging Cell* 11(1):162-168, 2012.
338. Gruszka AM, Martinelli C, Sparacio E, **Pelicci PG**, de Marco A. The concurrent use of N- and C-terminal antibodies anti-nucleophosmin 1 in immunofluorescence experiments allows for precise assessment of its subcellular localisation in acute myeloid leukaemia patients. *Leukemia* 26(1):159-622, 2012.
339. Marcu R, Rapino S, Trinei M, Valenti G, Marcaccio M, **Pelicci PG**, Paolucci F, Giorgio M. Electrochemical study of hydrogen peroxide formation in isolated mitochondria. *Bioelectrochemistry* 85:21-8, 2012.
340. Salamone F, Li Volti G, Titta L, Puzzo L, Barbagallo I, La Delia F, Zelber-Sagi S, Malaguarnera M, **Pelicci PG**, Giorgio M, Galvano F. Moro orange juice prevents fatty liver in mice. *World J Gastroenterol* 18(29):3862-8, 2012.
341. Vashistha H, Singhal PC, Malhotra A, Husain M, Mathieson PW, Saleem MA, Kuriakose C, Seshan S, Wilk A, Delvalle L, Peruzzi F, Giorgio M, **Pelicci PG**, Smithies O, Kim HS, Kakoki M, Reiss K, Meggs LG. Null Mutations at the p66 and Bradykinin 2 Receptor Loci Induce Divergent Phenotypes in the Diabetic Kidney. *Am J Physiol Renal Physiol* 303(12):F1629-40, 2012.

2013

342. Albiero M, Poncina N, Tjwa M, Ciciliot S, Menegazzo L, Ceolotto G, Vigili de Kreutzenberg S, Moura R, Giorgio M, **Pelicci PG**, Avogaro A, Fadini GP. Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. *Diabetes* 2013 Nov 22. [Epub ahead of print].

343. Beltrami E, Ruggiero A, Busuttill R, Migliaccio E, **Pelicci PG**, Vijg J, Giorgio M. Deletion of p66Shc in mice increases the frequency of size-change mutations in the lacZ transgene. *Aging Cell* 12(2):177-83, 2013.
344. Beltrami E, Valtorta S, Moresco R, Marcu R, Belloli S, Fassina A, Fazio F, **Pelicci PG**, Giorgio M. The p53-p66Shc apoptotic pathway is dispensable for tumorsuppression whereas the p66Shc-generated oxidative stress initiatestumorigenesis. *Curr Pharm Des* 19(15):2708-14, 2013.
345. Bock F, Shahzad K, Wang H, Stoyanov S, Wolter J, Dong W, **Pelicci PG**, Kashif M, Ranjan S, Schmidt S, Ritzel R, Schwenger V, Reymann KG, Esmon CT, Madhusudhan T, Nawroth PP, Isermann B. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. *Proc Natl Acad Sci U S A* 110(2):648-53, 2013.
346. Campaner S, Viale A, De Fazio S, Doni M, De Franco F, D'Artista L, Sardella D, **Pelicci PG**, Amati B. A non-redundant function of cyclin E1 in hematopoietic stem cells. *Cell Cycle* 12(23):1-10, 2013.
347. Castelli M, Pieroni S, Brunacci C, Piobbico D, Bartoli D, Bellet MM, Colombo E, **Pelicci PG**, Della Fazia MA, Servillo G. Hepatocyte odd protein shuttling (HOPS) is a bridging protein in the nucleophosmin-p19 Arf network. *Oncogene* 32(28):3350-8, 2013.
348. Dellino GI, Cittaro D, Piccioni R, Luzi L, Banfi S, Segalla S, Cesaroni M, Mendoza-Maldonado R, Giacca M, **Pelicci PG**. Genome-wide mapping of human DNA-replication origins: Levels of transcription at ORC1 sites regulate origin selection and replication timing. *Genome Res* 23(1):1-11, 2013.
349. Furia L, **Pelicci PG**, Faretta M. A computational platform for robotized fluorescence microscopy (I): High-content image-based cell-cycle analysis. *Cytometry A* 83(4):333-43, 2013.
350. Furia L, **Pelicci PG**, Faretta M. A computational platform for robotized fluorescence microscopy (II): DNA damage, replication, checkpoint activation, and cell cycle progression by high-content high-resolution multiparameter image-cytometry. *Cytometry A* 83(4):344-55.
351. Gambino V, De Michele G, Venezia O, Migliaccio P, Dall'olio V, Bernard L, Minardi SP, Fazia MA, Bartoli D, Servillo G, Alcalay M, Luzi L, Giorgio M, Scrabble H, **Pelicci PG**, Migliaccio E. Oxidative stress activates a specific p53 transcriptional-response that regulates cellular senescence and aging. *Aging Cell* 12(3):435-45, 2013.
352. Insinga A, Cicalese A, Faretta M, Gallo B, Albano L, Ronzoni S, Furia L, Viale A, **Pelicci PG**. DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions. *Proc Natl Acad Sci U S A* 110(10):3931-6, 2013.
353. Mallardo M, Caronno A, Pruneri G, Raviele PR, Viale A, **Pelicci PG**, Colombo E. NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novelmouse model. *Leukemia* 27(11):2248-51, 2013.
354. Mazzarella L, Disalvatore D, Bagnardi V, Rotmensch N, Galbiati D, Caputo S, Curigliano G, **Pelicci PG**. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. *Eur J Cancer* 49(17):3588-97, 2013.
355. Napolitano G, Amente S, Lavadera ML, Di Palo G, Ambrosio S, Lania L, Dellino GI, **Pelicci PG**, Majello B. Sequence-specific double strand breaks trigger P-TEFb-dependent Rpb1-CTD hyperphosphorylation. *Mutat Res* 749(1-2):21-7, 2013.
356. Ramsey JJ, Tran D, Giorgio M, Griffey SM, Koehne A, Laing ST, Taylor SL, Kim K, Cortopassi GA, Lloyd KC, Hagopian K, Tomilov AA, Migliaccio E, **Pelicci PG**, McDonald RB. The Influence of Shc Proteins on Life Span in Mice. *J Gerontol A Biol Sci Med Sci* 2013 Dec 14. [Epub ahead of print]
357. Raule N, Sevini F, Li S, Barbieri A, Tallaro F, Lomartire L, Vianello D, Montesanto A, Moilanen JS, Bezrukov V, Blanché H, Hervonen A, Christensen K, Deiana L, Gonos ES, Kirkwood TB, Kristensen P, Leon A, **Pelicci PG**, Poulain M, Rea IM, Remacle J, Robine JM, Schreiber S, Sikora E, Eline Slagboom P, Spazzafumo L, Antonietta Stazi M, Toussaint O, Vaupel JW, Rose G, Majamaa K, Perola M, Johnson TE, Bolund L, Yang H, Passarino G, Franceschi C. The co-occurrence of mtDNA mutations on different oxidative phosphorylation subunits, not detected by haplogroup analysis, affects human longevity and is population specific. *Aging Cell* 2013 Dec 17. doi: 10.1111/accel.12186. [Epub ahead of print]
358. Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, Martinelli G, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GE, Luzi L, Alcalay M, Dellino GI, **Pelicci PG**. Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. *Blood Cancer J* 3:e147, 2013.
359. Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S, Altucci L, **Pelicci PG**, Chiocca S, Johnstone RW, Minucci S. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. *Blood* 2013 121(17):3459-68. Feb 25.
360. Savino C, **Pelicci PG**, Giorgio M. The P66Shc/Mitochondrial Permeability Transition Pore Pathway Determines Neurodegeneration. *Oxid Med Cell Longev* 2013:719407, 2013.
361. Soncini M, Santoro F, Gutierrez A, Frigè G, Romanenghi M, Botrugno OA, Pallavicini I, **Pelicci PG**, Di Croce L, Minucci S. The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia. *Biochim Biophys Acta* 1832(1):114-20, 2013.

362. Trinei M, Migliaccio E, Bernardi P, Paolucci F, **Pelicci P**, Giorgio M. p66Shc, mitochondria, and the generation of reactive oxygen species. *Methods Enzymol* 528:99-110, 2013.

2014

363. Martinoli C, Gandini S, Luise C, Mazzarol G, Confalonieri S, **Pelicci P**, Testori A, Ferrucci PF. Maspin expression and melanoma progression: a matter of sub-cellular localization. *Mod Pathol* 27(3):412-9, 2014.
364. Masi G, Mercati D, Vannuccini E, Paccagnini E, Riparbelli MG, Lupetti P, **Pelicci PG**, Baldari CT, Ulivieri C. p66Shc regulates vesicle-mediated secretion in mast cells by affecting F-actin dynamics. *J Leukoc Biol* 95(2):285-92, 2014.
365. Patrusi L, Capitani N, Cannizzaro E, Finetti F, Lucherini OM, **Pelicci PG**, Baldari CT. Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc. *Cell Death Dis* 5:e1068, 2014.
366. Petrella F, Toffalorio F, Brizzola S, De Pas TM, Rizzo S, Barberis M, **Pelicci P**, Spaggiari L, Acocella F. Stem cell transplantation effectively occludes bronchopleural fistula in an animal model. *Ann Thorac Surg* 97(2):480-3, 2014.
367. Toffalorio F, Belloni E, Barberis M, Bucci G, Tizzoni L, Pruneri G, Fumagalli C, Spitaleri G, Catania C, Melotti F, **Pelicci PG**, Spaggiari L, De Pas T. Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids. *Br J Cancer* 110(5):1244-9, 2014.

List of invited reviews

1. Falini B, Martelli MF, Tarallo F, Tabilio A, Aversa F, Loreti G, **Pelicci PG**, Mason DY. La biopsia osteomidollare. Diagnostica istopatologica ed analisi immunoistologica con anticorpi monoclonali. *Medicina* 3:179-94, 1983.
2. **Pelicci PG**, Tabilio A, Vainchenker W, Testa U. The role of phorbol esters in the control of the proliferation and differentiation of hematopoietic cells. *Haematologica* 68:411-26, 1983.
3. Lanfrancone L, **Pelicci PG**, Dalla Favera R. Structure and expression of translocated c-myc oncogenes: specific differences in Endemic, sporadic and AIDS-associated Forms of Burkitt Lymphomas. *Curr Top Microbiol Immunol* (M. Potter, ed.), (Springer, publ.)132:257-65, 1986.
4. Dalla Favera R, Lombardi L, **Pelicci PG**, Lanfrancone L, Cesarman E, Neri A. Mechanism of activation and biological role of the c-myc oncogene in B-cell lymphomagenesis. *Ann NY Acad Sci* 511:207-18, 1987.
5. Knowles DM, **Pelicci PG**, Dalla Favera R. Immunoglobulin and T cell receptor beta chain gene DNA probes in the diagnosis and classification of human lymphoid neoplasia. *Mol Cell Probes* 1:15-31, 1987.
6. **Pelicci PG**, Knowles DM, Dalla Favera R. Analisi dei geni del T-cell Receptor nelle neoplasie linfoidi. *Haematologica* 72:75-7, 1987.
7. Knowles DMK, Chamulak G, Subar M, **Pelicci PG**, Dugan M, Burke JS, Raphael B, Dalla Favera R. Clinicopathologic, immunophenotypic and molecular genetic analysis of AIDS-associated lymphoid neoplasia: clinical and biologic implications. *Pathol Annual* 23 (Pt 2):33-67, 1988.
8. Moretta A, Bottino C, Pende D, Tripodi G, Orengo AM, Millo R, **Pelicci PG**, Ciccone E, Moretta L Human T lymphocytes expressing TCR gamma/delta. *Res Immunol* 141:630-5, 1990.
9. Moretta L, Ciccone E, Ferrini S, **Pelicci PG**, Mingari MC, Zeromski J, Bottino C, Grossi C, Moretta A. Molecular and cellular analysis of human T lymphocytes expressing gamma/delta T cell receptor. *Immunol Rev* 120:117-35, 1991.
10. **Pelicci PG**, Grignani F. Molecular biology in onco-hematology. *Haematologica* 76 (Suppl 3):11-8, 1991.
11. Pandolfi PP, Alcalay M, Longo L, Fagioli M, Zangrilli D, Grignani F, Mencarelli A, Biondi A, Rambaldi A, Lo Coco F, Grignani F, **Pelicci PG**. Molecular genetics of t(15;17) of acute promyelocytic leukemia (APPL). *Leukemia* 6 (Suppl 3):S120-2, 1992.
12. Biondi A, Rambaldi A, Pandolfi PP, Alcalay M, Rossi V, Giudici G, Lo Coco F, **Pelicci PG**. Molecular genetics of the t(15;17) translocation in acute promyelocytic leukemia. *Recent Results Cancer Res*, 131:345-59, 1993.
13. Ferrucci PF, Rogaia D, Tomassoni L, Liberatore C, Ruthardt M, Lo Coco F, Biondi A, Grignani F, Alcalay M, Fagioli M, Grignani F, **Pelicci PG**. Il contributo della biologia molecolare nella clinica delle leucemie acute: l'esempio della promielocitica. *Haematologica* 91-96, 1993.
14. Grignani F, Fagioli M, Ferrucci PF, Alcalay M, **Pelicci PG**. The Molecular Genetics of Acute Promyelocytic Leukemia. *Blood Rev* 7:87-93, 1993.

15. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, **Pelicci PG**. Acute Promyelocytic Leukemia: from genetics to treatment. Blood 83:10-25, 1994.
16. Lanfrancone L, Pelicci G, **Pelicci PG**. Cancer genetics. Curr Opin Genet Dev 4:109-19, 1994.
17. Lo Coco F, **Pelicci PG**, Biondi A. Clinical relevance of the PML/RAR α gene rearrangement in acute promyelocytic leukaemia. Leuk Lymphoma 12:327-32, 1994.
18. Bonfini L, Migliaccio E, Pelicci G, Lanfrancone L, **Pelicci PG**. Not all Shc's roads lead to Ras. Trends Biochem Sci 21:257-61, 1996.
19. Brunel V, Lafage-Pochitaloff M, Alcalay M, **Pelicci PG**, Birg F. Variant and masked translocations in acute promyelocytic leukemia. Leuk Lymphoma 22:221-8, 1996.
20. Grignani F, **Pelicci PG**. Pathogenetic role of the PML/RAR α fusion protein in acute promyelocytic leukemia. Curr Top Microbiol Immunol 211:269-78, 1996.
21. Casini T, Grignani F, **Pelicci PG**. Genetics of APL and the molecular basis of retinoic acid treatment. Int J Cancer 70:473-4, 1997.
22. Di Fiore PP, **Pelicci PG**, Sorkin A. EH: a novel protein-protein interaction domain potentially involved in intracellular sorting. Trends Biochem Sci 22:411-3, 1997.
23. Sacchi S, Russo D, Avvisati G, Dastoli G, Lazzarino M, **Pelicci PG**, Bonora MR, Visani G, Grassi C, Iacona I, Luzi L, Vanzanelli P. All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi). Hematologica 82:106-21, 1997.
24. Cattaneo E, **Pelicci PG**. Emerging roles for SH2/PTB-containing SHC adaptor proteins in the developing mammalian brain. Trends Neurosci 21:476-81, 1998.
25. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, **Pelicci PG**. Molecular Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia. Blood 94(1):12-22, 1999.
26. Minucci S, Ciocce M, Maccarana M, **Pelicci PG**. The APL-associated fusion proteins. Haematologica 84(Suppl EHA-4):70-1, 1999.
27. Minucci S, **Pelicci PG**. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 10(2):215-25, 1999.
28. Luzi L, Confalonieri S, Di Fiore PP, **Pelicci PG**. Evolution of Shc functions from nematode to human. Curr Opin Genet Dev 10(6):668-74, 2000.
29. Alcalay M, Orleth A, Sebastiani C, Meani N, Chiaradonna F, Casciari C, Sciarpi T, Gelmetti V, Riganelli D, Minucci S, Fagioli M, **Pelicci PG**. Common themes in the pathogenesis of acute myeloid leukemia. Oncogene 20(40):5680-94, 2001.
30. Faretta M, Di Croce L, **Pelicci PG**. Effects of the AML-Associated Fusion Proteins on Nuclear Architecture. Semin Hematol 20(40):5680-94, 2001.
31. Minucci S, Nervi C, Lo Coco F, **Pelicci PG**. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20(24):3110-5, 2001.
32. Pearson M, **Pelicci PG**. PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 20(49):7250-6, 2001.
33. **Pelicci PG**. Inhibitors of histone-deacetylases. Tumori 87(6):S12-4, 2001.
34. **Pelicci PG**. A new class of anti-cancer drugs: HDAC-inhibitors. Suppl Tumori 1(4):S66, 2002.
35. Ventura A, **Pelicci PG**. Semaphorins: green light for redox signaling? Sci STKE 2002(155):PE44, 2002.
36. Di Fiore PP, **Pelicci PG**. Cell regulation. Curr Opin Cell Biol 15(2):125-7, 2003.
37. **Pelicci PG**. Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence? J Clin Invest 113(1):4-7, 2004.
38. Villa R, De Santis F, Gutierrez A, Minucci S, **Pelicci PG**, Di Croce L. Epigenetic gene silencing in acute promyelocytic leukemia. Biochem Pharmacol 68(6):1247-54, 2004.
39. Insinga A, Minucci S, **Pelicci PG**. Mechanisms of selective anticancer action of histone deacetylase inhibitors. Cell Cycle 4(6):741-3, 2005.
40. Insinga A, **Pelicci PG**, Minucci S. Leukemia-associated Fusion Proteins: Multiple Mechanisms of Action to Drive Cell Transformation. Cell Cycle 4(1):67-9, 2005.
41. Buonaguro FM, Lewis GK, **Pelicci PG**. Introducing infectious agents and cancer. Infect Agent Cancer 1:1, 2006.
42. Migliaccio E, Giorgio M, **Pelicci PG**. Apoptosis and aging: role of p66Shc redox protein. Antioxid Redox Signal 8(3-4):600-8, 2006.
43. Minucci S, **Pelicci PG**. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1):38-51, 2006.

44. Cosentino F, Francia P, Camici GG, **Pelicci PG**, Lüscher TF. Final Common Molecular Pathways of Aging and Cardiovascular Disease. Role of the p66Shc Protein. *Arterioscler Thromb Vasc Biol* 28(4):622-8, 2007. [Erratum in: *Arterioscler Thromb Vasc Biol*. 28(8):e154, 2008. Volpe, Massimo (added)].
45. Giorgio M, Trinei M, Migliaccio E, **Pelicci PG**. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? *Nat Rev Mol Cell Biol* 8(9):722-8, 2007.
46. Minucci S, **Pelicci PG**. Determinants of oncogenic transformation in acute promyelocytic leukemia: the hetero-union makes the force. *Cancer Cell* 12(1):1-3, 2007.
47. Trinei M, Berniakovich I, Beltrami E, Migliaccio E, Fassina A, **Pelicci P**, Giorgio M. P66 signals to age. *Aging* (Albany NY) 1(6):503-10, 2009.
48. Viale A, **Pelicci PG**. Awakening stem cells from dormancy: growing old and fighting cancer. *EMBO Mol Med* 1(2):88-91, 2009.
49. Mercurio C, Minucci S, **Pelicci PG**. Histone deacetylases and epigenetic therapies of hematological malignancies. *Pharmacol Res* 62(1):18-34, 2010.
50. Belloni E, Trubia M, Gasparini P, Micucci C, Tapinassi C, Confalonieri S, Nuciforo P, Martino B, Lo-Coco F, Di Fiore P, **Pelicci PG**. Chromosomal rearrangements in acute myeloid leukemia (AML). *Ecancermedalscience* 4:183, 2010.
51. Belloni E, Bonnomi E, Lahortiga I, Odero M, Di Fiore P, **Pelicci PG**. Spectral karyotyping (SKY). *Ecancermedalscience* 4:181, 2010.
52. Colombo E, Alcalay M, **Pelicci PG**. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. *Oncogene* 30(23):2595-609, 2011.
53. Pasi CE, Bonizzi G, **Pelicci PG**. Setting sights on the right target: p53 and stem cell division. *Cell Cycle* 9(12):2265-6, 2010.
54. Pasi CE, **Pelicci PG**. Inhibition of epithelial-to-mesenchymal transition: A novel tumor-suppressor function of p53? *Cell Cycle* 10(16), 2011.
55. **Pelicci PG**, Dalton P, Orecchia R. Heating cancer stem cells to reduce tumor relapse. *Breast Cancer Res* 13(3):305, 2011.
56. Bonizzi G, Cicalese A, Insinga A, **Pelicci PG**. The emerging role of p53 in stem cells. *Trends Mol Med* 18(1):6-12, 2012.
57. Adams D, Altucci L, Antonarakis SE, Ballesteros J, Beck S, Bird A, Bock C, Boehm B, Campo E, Caricasole A, Dahl F, Dermitzakis ET, Enver T, Esteller M, Estivill X, Ferguson-Smith A, Fitzgibbon J, Flicek P, Giehl C, Graf T, Grosveld F, Guigo R, Gut I, Helin K, Jarvius J, Küppers R, Lehrach H, Lengauer T, Lernmark A, Leslie D, Loeffler M, Macintyre E, Mai A, Martens JH, Minucci S, Ouwehand WH, **Pelicci PG**, Pendeville H, Porse B, Rakan V, Reik W, Schrappe M, Schübeler D, Seifert M, Siebert R, Simmons D, Soranzo N, Spicuglia S, Stratton M, Stunnenberg HG, Tanay A, Torrents D, Valencia A, Vellenga E, Vingron M, Walter J, Willcocks S. BLUEPRINT to decode the epigenetic signature written in blood. *Nat Biotechnol* 30(3):224-6, 2012.
58. Riva L, Luzi L, **Pelicci PG**. Genomics of acute myeloid leukemia: the next generation. *Frontiers in Oncology* 2:40, 2012.
59. Pallavi R, Giorgio M, **Pelicci PG**. Insights into the beneficial effect of caloric/ dietary restriction for a healthy and prolonged life. *Front Physiol* 3:318, 2012
60. Verga Falzacappa MV, Ronchini C, Reavie LB, **Pelicci PG**. Regulation of self-renewal in normal and cancer stem cells. *FEBS J*. 279(19):3559-72, 2012
61. **Pelicci PG**, Dalton P, Giorgio M. The Other Face of ROS: a Driver of Stem Cell Expansion in Colorectal Cancer. *Cell Stem Cell* 12(6):635-6, 2013.
62. Mazza M, **Pelicci PG**. Is PML a Tumor Suppressor? *Frontiers in Oncology* 3:174, 2013.
63. Migliaccio E, Giorgio M, **Pelicci PG**. p53 and aging: role of p66Shc. *Aging* (Albany NY) 5(7):488-9, 2013.
64. Insinga A, Cicalese A, **Pelicci PG**. DNA damage response in adult stem cells. *Blood Cells Mol Dis* 52(4):147-151, 2014.

Book Chapters

1. **Pelicci PG**, Thomopoulos P, Tabilio A, Vainchenker W, Titeux M, Gourdin MF, Rochant H, Rambotti P, Martelli MF, Grignani F, Testa U: Phorbol esters inhibit transferrin binding to human hematopoietic cell lines. *Frontiers in Experimental Hematology*. Ed. by Torelli U, Bagnara GP, Brunelli MA, Castaldini C, Di Prisco AV. Sero Symbiosia, Roma, Vol 4:85-7, 1983.

2. Tabilio A, **Pelicci PG**, Mannoni P, Vainchenker W, Testa U, Rochant H, Breton-Gorius J, Falini B, Martelli MF, Grignani F: Modulation of granulocytic and megakaryocytic differentiation markers by different inducers in the K562 cell line. Frontiers in Experimental Hematology. Ed. by Torelli U, Bagnara GP, Brunelli MA, Castaldini C, Di Prisco AV. Serono Symposia, Roma, Vol 4:169-72, 1983.
3. Lanfrancone L, **Pelicci PG**, Cesarman E, Dalla Favera R: Mechanism of oncogene activation in human hematopoietic tumors. In: New trends in experimental Hematology: Oncogenes - stem cells - Bone Marrow Transplantation. Ed. by Peschle C and Rizzoli C. Ames Serono Publ., Num. 7:196-203, 1984.
4. **Pelicci PG**, Flug F, Bonetti F, Knowles DM, Dalla Favera R: Immuglobulin and T-cell receptor gene rearrangement in B and T-cell neoplasm. In: New trends in Experimental Hematology. Oncogenes - stem cells - Bone Marrow Transplantation. Ed. by Peschle C and Rizzoli C. Ames Serono Publ., Num. 7:79-86, 1984.
5. **Pelicci PG**, Lanfrancone L, Brathwaite MD, Wolman SR, Tabilio A, Dalla Favera R: Oncogene (c-myc, c-myb) amplification in acute Myelogenous leukaemia. In: Monoclonal Antibodies in Haemopathology. Ed. by Grignani F, Martelli MF, Mason DY. Raven Press, New York, 26:79-86, 1985.
6. **Pelicci PG**, Subar M, Littman DR, Dalla Favera R: Molecular diversity of the human T gamma gene. Genotypic, Phenotypic and Functional Aspects of Hemopoiesis. Grignani F, Martelli MF, Mason D (Eds). Raven Press, New York, Vol 41:167, 1987.
7. Tabilio A, Lanfrancone L, Stefani S, **Pelicci PG**, Falzetti F, Carotti A, Grignani F, Martelli MF: Evidence favouring myeloid origin in acute undifferentiated leukemias: Absence of immunoglobulin and B-T cell receptor gene rearrangements in CD33 and/or CD13 positive acute leukemias. Genotypic, Phenotypic and Functional Aspects of hemopoiesis. Grignani F, Martelli MF, Mason D (Eds). Raven Press, New York, Vol 41:59, 1987.
8. Alcalay M, Lanfrancone L, Montanucci M, Talamo G, Grignani F, **Pelicci PG**: Structure and function of the c-fes oncogene. Oncogenes and Growth Factors in Onco-hematology. Ed. by Aglietta M, Saglio G, Gavosto F, pp 97-100, 1988.
9. Lanfrancone L, Poiesz B, Tabilio A, Falcinelli F, Donti E, Grignani F, **Pelicci PG**: Normal human macrophages: a novel system to study the role of oncogenes in cell proliferation and differentiation. In: Oncogenes and Growth Factors in Onco-hematology. Ed. by Aglietta M, Saglio G, Gavosto F, pp 88-91, 1988.
10. Lania L, Pascucci A, Pannuti A, Pengue G, Feliciello I, Lanfrancone L, **Pelicci PG**, La Mantia G: Expression of human finger genes during myeloid differentiation. In: Oncogenes and Growth Factors in Onco-hematology. First National Symposium. Ed. by Aglietta M, Saglio G, Gavosto F, p. 76, 1988.
11. Testa U, Carè A, Montesoro E, Fossati C, Giannella G, Masciulli R, Fagioli M, Bulgarini D, Habetswallner D, Isacchi G, **Pelicci PG**, Peschle C: IL-2 dependent long term cultures of human LAK cells. Cytokines in hemopoiesis, oncology and AIDS, 1989.
12. Fagioli M, Carè A, Ciccone E, Moretta L, Moretta A, Meccia E, Testa U, Grignani F, Peschle C, **Pelicci PG**: Clonaggio del trascritto di 1.0 Kb da linfociti NK e g/d. Serono Symposia Reviews, 1991.
13. **Pelicci PG**, Grignani F: Acute Promyelocytic Leukemia: rearrangements of the RARa and myl genes. In: Progress and perspectives in chemoprevention. Ed. De Paolo G, Sporn M, Veronesi U. Raven Press 79:233-42, 1992.
14. Grignani F, Fagioli M, Alcalay M, Ferrucci PF, Tomassoni L, Rogaia D, Grignani F, **Pelicci PG**: The molecular genetics of acute promyelocytic leukemia. Molecular Bases of Human Diseases. Ed. by Polli EE, 1993.
15. Grignani F, Fagioli M, Alcalay M, Tomassoni L, Rogaia D, Grignani F, **Pelicci PG**: Molecular Pathogenesis of Acute Promyelocytic Leukaemia. Hematopoietic growth factors: Oncogenes and cytokines in clinical hematology. Karger, Basel, Vol. 106:148-59, 1993.
16. Alcalay M, Fagioli M, Grignani F, Ferrucci PF, Tomassoni L, Rogaia D, Liberatore C, Ruthardt M, Mencarelli A, Grignani F, **Pelicci PG**: Molecular genetics of the acute promyelocytic leukemia. Serono Symposia, Vol. 2, 1993.
17. Grignani F, Fagioli M, Alcalay M, Ferrucci PF, Tomassoni L, Rogaia D, Liberatore C, Ruthardt M, Mencarelli A, Grignani F, **Pelicci PG**: Pathogenetic relevance of the acute promyelocytic leukemia-specific PML/RARa fusion proteins. Serono Symposia, Vol. 2, 1993.
18. Grignani F, Grignani Fr, Rogaia D, Tomassoni L, Ruthardt M, Liberatore C, Ferrucci PF, **Pelicci PG**: La patogenesi molecolare della leucemia acuta promielocitica e le sue implicazioni per la diagnosi e la terapia. Haematologica, Vol.78, Supplement to No.6, December 1993.
19. Alcalay M, Grignani Fr, Ferrucci PF, Fagioli M, Mencarelli A, Grignani F, **Pelicci PG**: The acute promyelocytic leukemia PML/RARa protein affects differentiation and survival of myeloid precursor cells. Retinoids: From Basic Science to Clinical Applications, Livrea and Vidali Eds. Birkhauser Verlag Basel/ Switzerland, pp 357-66, 1994.
20. Biondi A, Rambaldi A, Rossi V, Luciano A, Cavana M, Lo Coco F, Diverio D, Pandolfi PP, Alcalay M, Bartram CR, **Pelicci PG**: PCR approach for the evaluation of minimal residual disease in acute leukemia. Molecular Diagnosis and Monitoring of Leukemia and Lymphoma, Borden, Goldman, Grignani Eds, pp 211-19, 1994.

21. Diverio D, Pandolfi PP, Biondi A, Rossi V, Rambaldi A, **Pelicci PG**, Lo Coco F: Molecular monitoring of the Acute Promyelocytic Leukemia clone following different treatment modalities. Molecular Diagnosis and Monitoring of Leukemia and Lymphoma, Borden, Goldman, Grignani Eds, pp 87-92, 1994.
22. Fagioli M, **Pelicci PG**: Structure and expression pattern of the PML gene. Normal and Malignant Hematopoiesis, Ed. Mihich and Metcalf, Plenum Press, 13:157-71, 1995.
23. Grignani F, Aversa F, Donti E, Grignani Fr, Nicoletti I, **Pelicci PG**: Leucemie acute non linfoidi. Patogenesi molecolare e terapia. Il Policlinico, Sez. Pratica, Ed. Pozzi, 102(7/8):377-89, 1995.
24. Grignani F, **Pelicci PG**: Molecular biology of acute promyelocytic leukemia. Hormons and Cancer, Ed. By Vedeckis W, Birkhauser, Boston, pp 577-605, 1996.
25. **Pelicci PG**: Tumori: marcatori genetici. Enciclopedia Medica Italiana, pp 6016-23, 2000.
26. Giorgio M, **Pelicci PG**: Mouse Models and Longevity. Oxidative Stress and Aging: diagnostic, intervention and longevity, World Scientific Publishing Co.Pte.Ltd., pp 1262-75, 2002.
27. Kajstura J, LeCapitaine N, Loredi M, Giorgio M, Mitchell TS, Valentini S, Rotatori F, **Pelicci PG**: Cardiac stem cells and diabetic cardiomyopathy. Chapter 16 - Part IV Cardiac progenitor cells and heart failure - Cardiovascular Regeneration and Stem Cell Therapy, Blackwell Futura Publishing, pp 161-9, 2007.
28. Viale A, **Pelicci PG**: Regulation of Self-Renewing Divisions in Normal and Leukaemia Stem Cells (Chapter 7). Cell Cycle Deregulation in Cancer, G.H. Enders Ed., Current Cancer Research, Part 3, 109-125, 2010.
29. Cambiaghi V, Giuliani V, Lombardi S, Marinelli C, Toffalorio F, **Pelicci PG**: Trim Proteins in Cancer (Chapter 6). TRIM/RBCC Proteins, Landes Biosciences, pp 77-91, 2012